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GLOSSARY AND ABBREVIATIONS 
CRF Case Report Form 
 
HAART Highly Active Antiretroviral Therapy 
 
ART Antiretroviral Therapy 
 
PI Protease Inhibitor 
 
NRTI Nucleoside Reverse Transcriptase Inhibitor 
 












EFV  Efavirenz 
 
IFU Infant Follow Up 
 
MTCT Mother-To-Child Transmission 
 
MOP Manual Of Operations 
 
APR                  Antiviral Pregnancy Registry 
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SUBSTANTIVE CHANGES FROM DART INFANT FOLLOW UP PROTOCOL V1.1 
 
Major 
Section 1, 3 & 4.1 
• Extension of the period of follow-up of infants to the end of the DART trial. This was 
previously to 72 weeks of age 
Section 2.2 
• As the DART trial was extended to 6 years, infants will now be followed to December 31st 
2008 with a rollover period until September 2009 
Section 1.3, 1.4, 4.1 & 6.2 
• Addition of 6 monthly follow-up visits for infants after 72 weeks of age, as indicated in the 
new schedule flow sheet in section 1.4 
Section 1.4, 4.1 & 6.5 
• Changes to DNA PCR (or RNA) testing plan; the previous routine test at 24 weeks has been 
moved to 48 weeks. A test is now optional at weeks 12 and 24 depending on symptoms 
and breastfeeding history. All other tests are as previously and a new flow diagram 
(section 6.5) shows the test schedule 
Section 4.1 & 6 
• Now includes further guidelines for enrolment and collection of retrospective and 
prospective data 
Section 4.1 
• Removal of X-rays of long bones from follow up, (noting that all bone fractures are still 
captured as events during routine follow up) 
Section 4.1, 5.1 & 6.7 
• Collection and storage of breastmilk samples has been made optional for breastfeeding 
mothers and is no longer a requirement of the inclusion criteria 
Section 5.1 & 6.1 
• Removal from inclusion criteria in section 5.1 that only infants less than 1 year of age are 
eligible. DART infants already born and older than 1 year are now eligible and will be 
offered enrolment (section 6.1) 
Section 6.4 
• Removal of routine urine chemistries unless clinically indicated; protocol now only requires 
routine urine storage as indicated in section 6.8 
Appendix 1 
• Changes to patient information sheet template (Appendix 1) in line with protocol version 
1.2 
Appendix 2 
• Changes to study consent form (Appendix 2) in line with protocol version 1.2 and to 
include breastmilk sampling and storage as optional 
Appendix 3 
• Toxicity gradings have been updated. Use of WHO (2007) rather than DAIDS (2004) 
gradings for neutrophil toxicity to recognise that infants and children of African origin have 
a lower normal range of absolute neutrophil counts 
Appendix 4 




• These have been updated 
Section 2.3-2.7 
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1. Summary 
 
1.1 AIM and OBJECTIVES 
The overall aim of this study is to identify HIV infected pregnant women in the DART trial who are 
receiving triple drug ART, and to follow their infants to the end of the DART study. Infants born to 
women in the adult DART study will be monitored for growth and development, renal 
abnormalities and bone fractures, grade 3 and 4 adverse events, HIV status and survival. Any 
infected infants needing ART may be enrolled into the AntiRetroviral Research fOr Watoto 
(ARROW) trial if eligible.  
 
The specific objectives are: 
• To determine clinical, haematological, biochemical and bone adverse effects in infants born 
to women receiving ART in DART. 
 
• To monitor growth and development of infants including height, weight and developmental 
milestones. 
 
• To determine rates of HIV infection in infants born to women in the DART study using DNA 
or RNA PCR tests performed in real-time or retrospectively on stored specimens. 
 
• To measure antiretroviral drug levels (TDF, ZDV, 3TC, ABC and NVP in particular) in breast 
milk in women who breastfeed and to undertake drug level measurements in plasma from 
their infants. 
 
1.2 DESIGN and POPULATIONS 
DART Infant Follow Up (IFU) is a longitudinal observational study. All infants born to mothers in 
the DART study will be approached for enrolment and followed up until completion of the DART 
Trial. 
 
1.3 FOLLOW-UP  
All prospectively enrolled children will be seen at around 2 weeks after birth for completion of the 
DART Case Record Form (CRF) for Pregnancy Outcome and enrolment into the IFU study.  
Enrolled infants will also be seen at weeks 6, 12 and 24 after birth, and then every 24 weeks 
which will coincide with the mother’s scheduled DART visit. Infants already born to DART mothers 
before the start of IFU will be followed up prospectively according to their age and the above visits 
and data also collected retrospectively. The protocol scheduled visits can be seen in the flowsheet 
in section 1.4.
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1.4 FLOWSHEET 
 
If a child is seen more frequently than indicated, a prospective follow-up form should be completed at each visit. 
The flow sheet indicates the ideal in terms of tests performed. At minimum, if a child enrols at or before 6 weeks of age then tests should be 
undertaken at 6 weeks and again at 24 and 72 weeks and then at 24 weeks following this. If a child enrols at a later age then please refer to the DART 
IFU Manual Of Operations (MOP, version 1.1) CRF guidelines 
(a)  Clinical assessment:  including medical history, height, weight, head circumference, motor development, occurrence of fractures or other Grade 3 or 4 adverse events, and 
presence of any HIV-related signs and symptoms (Appendix 4)  
(b) Biochemistry I:  creatinine, BUN, AST or ALT, sodium, potassium (2ml) 
 Biochemistry II: where possible, calcium, phosphate, alkaline phosphatase from the same sample as Biochemistry I 
(c) Haematology:  haemoglobin, MCV, WBC, lymphocytes, neutrophils, platelets (1ml)  
(d) Urine storage/dipstick: store 2mls of urine if possible which can be obtained from nappy/diaper if necessary. Perform dipstick test prior to storage 
(e) DNA (or RNA) PCR:          at 6 weeks; if positive, confirm with a second test immediately; if negative and unsure if breastfeeding or not confirm negative at 24 weeks. Repeat PCR    
at 48 weeks in all asymptomatic patients. Test if symptomatic at any time or if breastfeeding has ceased since the last visit. Exact time of testing babies 
                                               can be flexible and take into account other factors including wish for caregivers to test earlier. See flow diagram in section 6.5 
(f) Plasma storage:              from a total 5ml (1 teaspoon, includes remainder from haematology/biochemistry) blood draw to be separated and stored locally at 
                                               -80°C (see DART MOP for instructions for plasma handling and storage); cell pellet should be stored if feasible.  
(g)     Cotrimoxazole prophylaxis according to WHO guidelines (Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults in resource-  
limited settings, WHO 2006): continue until HIV infection can be excluded by HIV antibody testing (beyond 18 months of age) or virological testing 
(before 18 months of age). If breastfeeding, HIV infection must be excluded at least 6 weeks after cessation of feeding. 
For all tests/samples/assessments: those in brackets are optional. If possible store a specimen sample at week 2 (or use heel prick for dried blood spot storage) 































Signed informed consent  X              
Clinical assessment a  X X X X X X X X X X X X X 
Biochemistry I b (2ml)   X  X X X X X X X X X X 
Biochemistry II b   X  (X) (X) (X) (X) (X) (X) (X) (X) (X) (X) 
Haematology c (1ml)   X  X X X X X X X X X X 
Urine storage (up to 2ml) and dipstick test d   X  X X X X X X X X X X 
HIV DNA or RNA PCR e (1ml)   X (X) (X) X         
HIV ELISA/rapid test        X        
Specimen storage f(1ml+remainder) or blood spot 
if not enough blood to store 
 (X) X  X X X X X X X X X X 
Storage of breast milk samples from mother 
(optional) 
(X) (X) (X) (X) (X)          
Cotrimoxazoleg   X X X X (X) (X) (X) (X) (X) (X) (X) (X) 
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Mother to child HIV transmission (MTCT) remains the major mode of acquisition of HIV 
infection in children world-wide. The vertical transmission rates in Africa tend to be much 
higher than the developed world. More advanced disease and almost universal breastfeeding 
contribute to these higher rates. In developed countries implementation of PMTCT programs 
is a reality; most infected pregnant women are identified early and antiretroviral therapy 
provided to prevent MTCT. With more effective HIV care and treatment including effective 
antiretroviral therapy (ART), the risk of MTCT has been reduced to less than 2% in well 
resourced countries (1). However, African women do not have universal access to HIV 
testing in pregnancy and when available, acceptance of HIV testing and use of antiretroviral 
drugs for PMTCT is lower, typically between 40-80%. Therefore, understanding the impact 
of effective ART in pregnancy in an African population is a priority. 
 
2.2 DART study 
DART (Development of Antiretroviral Therapy) is a six year clinical endpoint randomised trial 
to evaluate monitoring practice and structured treatment interruptions in the management 
of ART in adults with HIV infection in Africa (www.ctu.mrc.ac.uk/dart). Among 3315 patients 
(2155 women) enrolled (recruitment completed October 2004), 2468 (74%) started combivir 
(co-formulated zidovudine (ZDV) and lamivudine (3TC)) plus tenofovir (TDF), 547 (16%) 
started ZDV+3TC plus nevirapine (NVP) and 300 (9%) started ZDV+3TC plus abacavir 
(ABC). Pregnant women were not eligible for enrolment into DART. However, some women 
have become pregnant during the study follow-up period. The DART International 
Coordinating Group has developed a manual of operations (MOP, appendix 5) for the 
management of pregnancy and delivery in DART, including the reporting of pregnancies and 
of their outcome.   
 
The MOP states that for women on first-line tenofovir + combivir, NVP should be given to 
the infant only within 4hours of birth, as it will not have been given to the mother. Babies 
could also receive ZDV+/-3TC for 1 week as well as this single dose of NVP, starting within 4 
hours of birth. However, giving all three may be difficult as liquid formulations have to be 
obtained. NVP could be given as part of a national program.  For mothers taking 
NVP+ZDV+3TC, NVP post-exposure prophylaxis should be given for the baby starting at 48 
hours. ZDV+/- 3TC could be added for 1 week, if this is feasible and available, as there are 
few other alternative regimens. Sites may deviate from this policy if individual circumstances 
indicate an alternative (see MOP, appendix 5, for further details). 
 
Although the DART MOP recommends good clinical practice for following babies born to 
HIV-infected women, ethics approval for DART does not cover consent for infant follow-up 
or collection of data on infants. Therefore it is critical to have a standard protocol to monitor 
the infants born to mothers in DART and to evaluate longer-term outcomes in these infants; 
particularly in those women receiving ZDV+3TC+TDF and ZDV+3TC+ABC where data are 
more limited. 
 
2.3 Tenofovir  
Tenofovir disoproxil fumarate (tenofovir DF; Viread), an ester prodrug of the nucleotide 
reverse transcriptase inhibitor (NRTI) tenofovir, is indicated in combination with other 
antiretroviral agents in the treatment of HIV infection. As a component of an antiretroviral 
regimen, oral tenofovir DF 300mg once daily is recommended. Tenofovir DF provides a 
simple and convenient once-daily dosage regimen, and is generally well tolerated and able 
to produce sustained suppression of viral replication. 
 
 
Follow-up of infants born in DART 
IFU protocol v1.2 July16th 2008                                              Page 12 of 53 
Animal Studies of Tenofovir in Pregnancy 
Reproduction studies have been performed in rats and rabbits at doses up to 14 and 19 
times the human dose based on body surface area comparisons and revealed no evidence of 
impaired fertility or harm to the foetus due to tenofovir. There are, however, no adequate 
and well-controlled studies in pregnant women. Because animal reproduction studies are not 
always predictive of human response, TDF should be used during pregnancy only if clearly 
needed (Viread Prescribing Information, Gilead Sciences 19th May 2008). 
 
Placental transfer of TDF has been studied in pregnant rhesus monkeys. Following daily 
subcutaneous doses of 30 mg/kg/day beginning on day 80 (beginning of second trimester) 
of gestation, the fetal/maternal ratio tenofovir concentrations was approximately 17% with 
measurements performed at gestational age 120 and 140 days (2). In addition, after 
subcutaneous administration of a single dose of tenofovir (30 mg/kg) to near-term pregnant 
macaques, the tenofovir level in the cord blood collected during C-section 2 hours later was 
60% of that in maternal blood (3). In this study, infant concentrations were a mean of 5.82 
+/- 1.4 mcg/ml. In addition, infant rhesus monkeys demonstrate a 5-fold decrease in 
clearance of tenofovir. The lower clearance is thought to be due to an immature kidney and 
suggests delayed excretion may also occur in neonates.  
 
Secretion in Breast Milk 
The Centers for Disease Control and Prevention recommend that HIV-infected mothers do 
not breast-feed their infants to avoid risking postnatal transmission of HIV. Studies in rats 
have demonstrated that tenofovir is secreted in milk. It is not known whether tenofovir is 
excreted in human milk. Because of both the potential for HIV transmission and the 
possibility for adverse reactions in nursing infants, Viread Prescribing Information (Gilead 
Sciences 19th May 2008) recommends that mothers are instructed not to breast-feed if they 
are receiving TDF. 
 
Human Experience of Tenofovir 
More than 12,000 patients have been treated with TDF alone or in combination with other 
antiretroviral medicinal products for periods of 28 days to 215 weeks in Phase 1-3 clinical 
trials and expanded access studies. A total of 1,544 patients have received TDF 300 mg 
once daily (QD) in Phase 1-3 clinical trials; over 11,000 patients have received TDF in 
expanded access studies (Viread U.S. Prescribing Information, Gilead Sciences 19th May 
2008). Tenofovir is usually well tolerated and the most common side effects include rash, 
diarrhoea headache, pain, depression, asthemia and nausea. Other side effects are rare but 
include osteoporosis, osteopenia, renal failure, lactic acidosis, hepatomegaly with steatosis 
and fat redistribution.  
 
Gilead Sciences contributes to the Antiviral Pregnancy Registry (APR) and uses this registry 
for tracking and following-up of all cases of pregnancy reported in patients receiving TDF in 
clinical practice. As of 31st July January 2006, a total of 231 post-marketing reports of 
pregnancies have been reported (4), with no evidence of any increase in congenital 
abnormalities (note that numbers are very small). Other pregnancy registers include 
increasing number of infants born to mothers taking Tenofovir (e.g. 75 babies in the 
National Study of HIV in Pregnancy and Childhood, P Tookey, personal communication). 
Overall in the UK study of around 4000 births, there was no evidence of an increase in 




This nucleoside reverse transcriptase inhibitor (NRTI) is also well tolerated but the 
hypersensitivity syndrome is one of its major side effects, reported in 3-5% of those on the 
drug. The hypersensitivity syndrome presents with fever, generalized rash, headache, 
nausea, fatigue and multi-organ involvement. Immediate and permanent discontinuation of 
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the drug is required and reintroduction of the drug is fatal. Therefore ABC should NEVER be 
reintroduced if the drug was discontinued because of the hypersensitivity syndrome.  
 
In the Antiviral Pregnancy Registry (APR), there were outcomes reported in 436 women 
taking ABC during the first trimester and 697 during the second and third trimesters (4).  
The numbers with first-trimester exposure are sufficient to detect a 2-fold increase in 
congenital abnormalities compared with normal children, and no such increase was 
observed.  
 
2.5 Zidovudine, Lamivudine and Nevirapine 
Zidovudine and lamivudine are NRTIs that have been used for prevention of mother to child 
transmission with no infant adverse events related to the drug. Therefore one would not 
expect serious adverse events due to the maternal dosing during pregnancy and subsequent 
exposure through breast milk. Haemoglobin did decrease by about 1 g/dl during the 6 
weeks when infants received continuous ZDV as post-exposure prophylaxis. However, this 
recovered as soon as ZDV was stopped in the ACTG 076 trial of ZDV to reduce MTCT (6).  
 
Nevirapine has been widely used to reduce MTCT in late pregnancy. In the APR, over 6331 
outcomes of pregnancy were reported to July 31st 2006, 2272 infants had maternal exposure 
to ARVs in the first trimester, 515 of these being to nevirapine. No significant increase in 
congenital abnormalities was observed (power to detect a 2-fold increase).  
 
2.6 Other Drugs 
Women may be on other drugs (e.g. for second line therapy) and it would be valuable to 
also follow infants born to these women. 
 
2.7 Rationale for this study 
Infants exposed to ART in pregnancy and during breastfeeding need to be monitored to 
ensure safety, particularly of TDF which is a relatively new antiretroviral drug, and is not yet 
licensed for use in children. As stated in the Viread Prescribing Information, TDF is placed in 
Pregnancy category B. The use of TDF in pregnant women has not been clearly established 
and studies such as the phase II trial on Tenofovir/Emtricitabine for PMTCT in Africa and 
Asia are small and still in recruitment stages so currently, there are no adequate and well-
controlled studies of TDF in pregnant women. Therefore every effort will be made to 
document any adverse events that may occur during the infant follow up. In addition, 
documentation of the effectiveness of ART given to the mother during pregnancy and 
breastfeeding, for her own disease, in reducing MTCT would be of value. It is acknowledged 
that these data will be descriptive only, and the accuracy of the estimate of vertical HIV 
transmission will depend on numbers (likely to be <300 mother-infant pairs). The need to 
follow and monitor the growth and development of infants born to mothers taking ART in 
pregnancy is recognized. In particular, as babies will have been exposed to TDF during 
intrauterine life and during breast-feeding, the need to monitor for renal function and where 
possible, bone abnormalities, is also critical. 
 
 
3. Aim and Objectives 
 
The overall aim of this study is to identify HIV infected pregnant women in the DART trial 
who are receiving triple drug ART, and to follow their infants to the end of the DART study. 
Infants born to women in the adult DART study will be monitored for growth and 
development, renal abnormalities and bone fractures, grade 3 and 4 adverse events, HIV 
status and survival. Any infected infants needing ART may be enrolled into the AntiRetroviral 
Research fOr Watoto (ARROW) trial if eligible.  
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The specific objectives are:  
 
1. To determine any clinical, haematological, biochemical and bone adverse effects in 
infants born to women receiving ART in DART. 
 
2. To monitor growth and development of infants including height, weight and motor 
developmental milestones. 
 
3. To determine rates of HIV infection in infants born to women in the DART study using 
DNA or RNA PCR tests performed in real-time or retrospectively on stored specimens. 
 
4. To measure antiretroviral drug levels (TDF, ZDV, 3TC, ABC and NVP in particular) in 
breast milk in women who breastfeed and to undertake drug level measurements in 
plasma from their infants. 
 
This protocol outlines a proposal for follow-up of babies born to women in the DART study. 
In addition (but not part of the current proposal), we plan to apply for funding for a 
proposal to undertake plasma pharmacokinetic studies in mothers taking TDF containing 





4.1 Design of study 
This observational study will enrol infants born to mothers in the adult DART trial.  As of 
June 2005, 76 women had been reported to have become pregnant (incidence about 2.3 per 
100 woman years at risk), but other women are likely to become pregnant before the end of 
the study.  
 
All infants born to women who are pregnant or become pregnant during the DART study will 
be eligible for IFU study. All pregnant women in the DART study and DART mothers who 
have given birth to an infant before the start of IFU will be counselled about IFU including 
the study procedures, benefits and risks. If they agree to participate and sign the informed 
consent form the infant will be enrolled. At birth the delivery information, gestational age 
and general condition will be documented, including method of infant feeding chosen by the 
mother. This information will be collected retrospectively for infants already born to DART 
mothers prior to the start of IFU. A maternal blood sample is taken close to the time of 
delivery for storage in the main DART trial.  At all visits the infants will have a history and 
physical exam. Infant blood will be collected for HIV DNA or RNA PCR during follow-up and 
for an HIV rapid test at 72 weeks to confirm final HIV status. If infants enrol past 72 weeks 
of age, then bloods will be taken for the HIV ELISA or rapid test only. 
 
Consent will be obtained from pregnant woman prior to delivery, or if infants are 
already born, signed consent will be obtained from the mother/carer before the 
infant is enrolled in the study. Breastfeeding DART mothers may be asked for 
breast-milk samples but this is not a requirement for entry into IFU. 
 
In the instances where an infant has died, the mother/carer may be approached for 
retrospective information. The decision to do this will be that of sites and at the clinicians 
discretion and will only be done if considered appropriate. 
 
Aim 1: Monitor clinical, haematological, biochemical and bone adverse events in 
infants exposed to Tenofovir and/or other antiretroviral drugs in utero and 
through breast milk. 
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At each routine visit the infants will have a history and examination to document clinical 
adverse events and blood will be collected to document haematological and biochemical 
adverse events. Data will also be collected retrospectively where available. 
 
Aim 2: Monitor growth and development of infants  
Infants born to DART mothers will be seen at 2, 6, 12, and 24 weeks after delivery and then 
every 24 weeks until the end of the DART study. Visits should coincide with the mother’s 
DART visit. Infants born before the start of IFU should follow the designated schedule (see 
flowsheet in section 1.4) according to their age. History and clinical exam including heights 
and weights will be documented at each routine visits and plotted on the standard child 
growth charts (for example, WHO). Developmental milestones will be monitored clinically – 
in particular motor milestones (using modified Bailey) will be documented. Study follow up 
visits will be done at the DART follow up clinic for all scheduled visits but the routine health 
care will be provided at other clinics.  
 
Aim 3: To determine rates of HIV infection in infants  
Since all the women will be receiving ART during pregnancy, the number of infants who will 
become infected is likely to be very low. Blood will be taken to determine the HIV status 
using DNA or RNA PCR (either in real-time or retrospectively) at 6 and 48 weeks If the 
results are positive then repeat HIV testing will be done to confirm the HIV status. Additional 
testing will be done at 24 weeks if negative but breastfeeding status is unknown. Infants 
should be tested at any time if symptomatic or if breastfeeding has stopped since the last 
visit. The final HIV test will be done at 72 weeks (or later if the child enrols after 72 weeks 
of age) using the standard HIV ELISA or HIV rapid tests. Plasma will be stored at all visits 
except week 12 for subsequent tests relating to HIV infection. 
 
Aim 4: To determine the antiretroviral drug concentrations in breast milk 
samples  
After delivery mothers in DART will be asked to express breast milk at the 2, 6, 12 and 24 
week time points and at the time of stopping breast-feeding (unless close to one of the 
other time-points). This is optional and not a requirement for enrolling into IFU. If mothers 
are breastfeeding at enrolment they will also be asked for breastmilk samples, which again 
is optional. The breast milk samples will be frozen and stored for later assays to evaluate 
Tenofovir, Lamivudine, Zidovudine and Abacavir drug levels as appropriate. 
 
4.2 Data collection 
Data will be recorded CRFs, the top copy/original should be sent to the Local DART Trials 
Centre for data entry and a copy kept at the local clinical centre. The type of data to be 
recorded is detailed in the Assessments and Procedures section (Section 6). 
 
 
5. Selection of Children 
 
5.1 Inclusion criteria 
i. Infants born to women in the DART study OR pregnant woman at term, 
enrolled in the DART study 
ii. Mother signed the informed consent form for her infant’s follow up  
iii. Mother willing to comply with the follow up study procedures and visits 
 
5.2 Exclusion criteria 
None 
 
5.3 Number and source of children 
It is planned to recruit all infants born to mothers in the DART study.  
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6. Assessments and Procedures 
 
6.1 Enrolment Procedure 
Pregnant women from the DART study will be identified at their respective centres and 
consent obtained late in pregnancy to enrol their infant into this follow up study. All 
pregnant women, close to term, will be given information about the objectives and rationale 
of the study and the possible risks (see the patient information sheets in Appendix 1). 
Women who have already given birth when the study starts will also be able to enrol their 
children into the study and will be given the patient information sheets. Retrospective and 
prospective data is to be collected from these children. 
 
Written informed consent to enrol into IFU will be obtained after explanation of the aims, 
methods, benefits and potential hazards of the study and BEFORE any study specific 
procedures are performed or any blood is taken for the study (see sample study consent 
form - Appendix 2). It will be made completely and unambiguously clear to the mother that 
they are free to refuse to allow their child to participate in the study, or withdraw their 
consent at any time and for any reason, without incurring any penalty or affecting the 
treatment of them or their child.  
 
Signed informed consent forms will be kept by the investigator and documented in the case 
report form and a copy given to the mother.  
 
6.2 Infant follow-up 
The infant follow up visits will occur at the same site as the mother’s routine DART visits 
(Entebbe, JCRC/Mulago, and Zimbabwe). The initial visit will occur at week 2 after delivery 
for pregnant women enrolled, when the DART outcome of pregnancy form will be completed 
(see DART pregnancy MOP, Appendix 5). Subsequent routine visits will be done at 6, 12, 24, 
and at 24 week intervals following this after birth, depending on the age of the infant at 
study entry. Follow up will continue until the completion of DART. An IFU 
Retrospective/Enrolment form will need to completed at the infants first visit, or, for infants 
born before the start of the study this may also be completed at a previous DART mothers 
visit. An IFU Prospective/Follow Up form should also be completed at the child’s first visit 
and then at every subsequent visit. For full CRF guidelines see the DART IFU MOP v1.1 
section 9.1 and Appendix 8 
 
At 6 weeks of age, all infants will be started on Cotrimoxazole for PCP prophylaxis and 
remain on it unless their HIV status is confirmed negative following WHO guidelines: HIV 
infection can be excluded by HIV antibody testing (beyond 18 months of age) or virological 
testing (before 18 months of age), if breastfeeding, HIV infection must be excluded at least 
6 weeks after cessation of feeding. The scheduled infant HIV tests can be seen in the flow 
diagram in section 6.5. Infants will receive treatment for acute illnesses at other clinics and 
only bring the infant to the DART clinic for the scheduled study visits. 
 
The flowchart (section 1.4) indicates the scheduled protocol assessments.  
 
6.3 Clinical examination and medical history 
A clinical examination will be performed at all follow-up protocol visits. At each visit the 
following should be recorded: 
 
 Body weight, height, head circumference, mid-upper arm circumference, 
temperature 
 Motor developmental milestones (modified Bailey)  
 Hospitalisations and/or Outpatient clinic attendances 
 Any grade 3 or 4 adverse event since last protocol visit 
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 Occurrence of solicited adverse events of any grade; namely fractures, clinical 
anaemia 
 HIV status when known 
 New signs and symptoms since last protocol visit 
 Hospital admissions since the last protocol visit 
 Feeding method since last protocol visit 
 Concomitant medication since last protocol visit 
 
If the child has died details will be recorded. 
 
6.4 Laboratory tests 
Where blood is taken at a scheduled protocol visit, safety monitoring tests will include:  
 
Haematology:  Haemoglobin, MCV, platelets 
white cell count, neutrophil and lymphocyte counts 
 
Biochemistry: Creatinine, BUN, ALT (SGOT) or AST (SGPT), sodium, 
potassium; Calcium, phosphate and alkaline phosphatase will 
be measured if possible 
 
(any other values provided by labs will also be recorded but may differ across sites) 
 
6.5 HIV testing 
Blood will be taken to determine the HIV status using DNA or RNA PCR at 6 weeks. RNA PCR 
may be used if available and easier at sites. If the infant is negative but breastfeeding, or if 
breastfeeding status unknown then a second PCR will be done at 24 weeks to confirm the 
negative test result. All infants will have a repeat PCR at 48 weeks. A PCR will also be done 
if an infant has signs or symptoms of HIV infection at any time or the mother has stopped 
breastfeeding since the last visit. 
 
If the infant has a positive HIV DNA or RNA PCR test result, a repeat blood sample will be 
collected as soon as possible to confirm the HIV status of the infant. An infant will be 
considered HIV infected after two consecutive positive HIV DNA or RNA PCR tests: further 
DNA or RNA tests need not then be performed. If the infant is asymptomatic through follow 
up, a HIV antibody test will be done at 72 weeks using the standard HIV ELISA or HIV rapid 
tests. After 72 weeks further antibody tests will only be done if a child develops symptoms, 
is still breastfeeding (in which case a HIV antibody test will be done every 6 months) or 6 
weeks after stopping breastfeeding, or if a child is enrolled at an age greater than 72 weeks 
and is untested. Please refer to the HIV testing flow diagram below. 
 
Infected infants will be followed and may be eligible to join the AntiRetroviral Research fOr 
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6.6 Plasma for storage 
1ml of EDTA blood will be collected at each protocol visit for plasma storage for 
retrospective analysis of HIV or any treatment related tests as appropriate (for example, HIV 
resistance testing or antiretroviral drug levels). A cell pellet will also be stored if possible. 
This blood will be the remainder of a total 5ml blood draw for storage and other tests. 
 
6.7 Breastmilk for storage 
 
The collection of breastmilk from breast-feeding women will be optional. If agreed, 
approximately 15 mls of breast milk will be expressed from each breast at 2, 6, 12 and 24 
weeks after delivery (depending on when breast feeding is stopped). The breast milk will be 
frozen and stored for later testing of antiretroviral drug levels. 
 
6.8 Urine storage 
 
Up to 2mls of urine will be collected from infants at weeks 6, 24 and then every scheduled 
24 week visit. This will be frozen and stored for retrospective analysis. 
 
7. Adverse events  
 
7.1 Adverse events 
Adverse events (AEs) are any untoward medical occurrences whether or not they are 
necessarily caused by or related to a medicinal product. Adverse events may be expected or 
unexpected. They may include side-effects, injury, toxicity or sensitivity reactions, abnormal 
laboratory results and intercurrent illnesses. An adverse reaction is an adverse event which 
is related to any dose administered to that subject. An unexpected adverse reaction is an 
adverse reaction, the nature and severity of which is not consistent with the information 
about the medicinal product in question set out in the SPC for that product (for products 
with a marketing authorisation) or the Investigator's Brochure relating to the study in 
question (for any other investigational product). 
 
It is particularly important to monitor adverse events closely in infants born to mothers in  
the DART study, as there is relatively little information about two of the drugs (TDF and 
ABC) that some pregnant women will have received. Therefore the follow-up form will 
explicitly solicit information about certain adverse events; namely fractures and clinical 
anaemia.  
 
7.2 Severity/grading of adverse events 
Standard criteria for grading laboratory and clinical events will be used for grading adverse 
events (Appendix 3). Adverse events will be categorised as HIV related, drug related and 
others.  Any adverse events of grade 3 or 4 will be reported on the IFU 
Retrospective/Enrolment and Prospective Follow-Up form.  
 
8. Statistics  
 
Because this study is observational, no analysis was conducted to determine the sample size 
requirement to test a hypothesis.  Instead, we show below the precision with which such a 
study could estimate HIV incidence and adverse events. 
 
There are 2155 women enrolled in the DART study: if the current pregnancy rate of 2.3 per 
100 woman years continues, then we would expect to see 150 pregnancies by the end of 
the study.  However, there were virtually no pregnancies in the first year of the study, and 
anecdotally more women are enquiring about becoming pregnant.  We therefore estimate 
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that there might be 200-400 pregnancies in women in the DART study.  However, a number 
of pregnancies so far have not been carried to term.  Therefore we expect anywhere 
between 100-400 infants born to women in the DART study. 
 
 
The following table shows the precision (95% C.I.) that one would obtain for a wide range 
of HIV transmission rates if 100-400 infants were enrolled in the study.  Exact tests were 
used to determine the 95% confidence intervals. 
 
 100 infants 200 infants 300 infants 400 infants 
Transmission 95% C.I. 95% C.I. 95% C.I. 95% C.I. 
1% (0.0%, 5.4%) (0.1%, 3.6%) (0.2%, 2.9%) (0.3%, 2.5%) 
2% (0.2%, 7.0%) (0.5%, 5.0%) (0.7%, 4.3%) (0.9%, 3.9%) 
4% (1.1%, 9.9%) (1.7%, 7.7%) (2.1%, 6.9%) (2.3%, 6.4%) 
6% (2.2%, 12.6%) (3.1%, 10.2%) (3.6%, 9.3%) (3.9%, 8.8%) 
8% (3.5%, 15.2%) (4.6%, 12.7%) (5.2%, 11.7%) (5.5%, 11.1%) 
 
The following table shows the precision (95% C.I.) that one would obtain for a wide range 
of adverse event rates if 100-400 infants were enrolled in the study.  Exact tests were used 
to determine the 95% confidence intervals. 
 
 100 infants 200 infants 300 infants 400 infants 
AE rate 95% C.I. 95% C.I. 95% C.I. 95% C.I. 
10% (4.9%, 17.6%) (6.2%, 15.0%) (6.8%, 14.0%) (7.2%, 13.4%) 
15% (8.6%, 23.5%) (10.4%, 20.7%) (11.2%, 19.6%) (11.6%, 18.9%) 
20% (12.7%, 29.2%) (14.6%, 26.2%) (15.6%, 25.0%) (16.2%, 24.3%) 
25% (17.9%, 34.7%) (19.2%, 31.6%) (20.2%, 30.3%) (20.8%, 29.5%) 
30% (21.2%, 40.0%) (23.7%, 36.8%) (24.9%, 35.5%) (25.5%, 34.8%) 
35% (25.7%, 45.2%) (28.4%, 42.0%) (29.6%, 40.7%) (30.3%, 39.9%) 
 
8.1 Analysis 
Data will be entered at each clinical site, and merged centrally at the MRC CTU. Statistical 
analysis of results will be undertaken under the supervision of senior statisticians at MRC 
CTU in collaboration with paediatricians and DART trial team members from Mulago 
Hospital, Entebbe, Harare and JCRC.  
 
Rates and cumulative proportions of HIV transmission, adverse events and death will be 
described using standard time to event methods. Longitudinal changes in growth and 
laboratory parameters will be described, and comparisons made between the HIV infected 
and serorevertors (uninfected) from Zimbabwe and Uganda. Analysis of growth parameters 
will be adjusted for age (z-scores). 
 
It is not expected that comparisons between infected and uninfected children will be 





9.1 Direct Access to Data 
Personal medical data may be reviewed at clinical centres by properly authorised individuals 
as part of monitoring and/or audit of the study, but such information will be treated as 
strictly confidential and will in no circumstances be made publicly available.  
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9.2 Confidentiality 
The child’s anonymity will be maintained. On all CRFs and specimens, children must not be 
identified by their names. Children will be identified by a unique substudy number, their 
mother’s DART Trial number, their initials and date of birth. The investigator will be asked to 
keep a separate Confidential Register which matches these identifiers with their names and 
which should be maintained by the investigator in strict confidence. 
 
 
10. Ethics Approval 
 
At each centre, one DART site investigator and one paediatrician will take on overall 
responsibility for the conduct of the study. They will submit the protocol and any subsequent 
amendments to the ethics committee.  
 
This protocol and the informed consent documents will be formally approved by the relevant 
ethics committee of each clinical centre and by a national ethics body, as required. A copy of 
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 Appendix 1: Sample information sheet  
(version 1.2) 
(to be printed on headed paper and translated as necessary) 
 
Follow up of infants born to HIV infected women in the DART study 
An information sheet for mothers/carers 
“Helping you decide whether or not your baby should join our study” 
 
Introduction 
You and your baby are being invited to take part in this research study, which is related to 
the DART trial. We would like you to know about the study before you make a decision. 
Please read this information carefully or have someone read it to you. The study staff will 
talk with you about this information. You are free to ask the clinic nurses or counsellors if 
you would like more information or clarification. You are free to ask questions about this 
study at any time. 
 
This sheet gives you information about this study. If you agree to allow your baby to take 
part in this study, you will be asked to sign a consent form. You will get a copy to keep. 
 
What is the reason for this study? 
During the pregnancy, the baby was exposed to antiretroviral therapy (ART). Until now 
there have been no reported increases in any kind of birth abnormalities in babies born to 
women taking ART in pregnancy. However this is still something that is being closely looked 
at. Some drugs have been used a lot in pregnant women and are probably safe, although 
the long-term effects on the baby are not yet known.  
 
Combivir+Nevirapine: Many women have become pregnant around the world whilst 
taking this combination: Most have remained very well, but some 
women and babies do get anaemic (low red cells) with ZDV.  
Combivir+Abacavir: There is less experience of abacavir use in pregnancy, so far no 
specific problems have been reported.  
Combivir+Tenofovir: There is less experience of TDF in pregnancy. So far no specific 
problems have been reported in babies. Concern that TDF could 
affect the baby’s bones has been expressed because it has been 
seen in some baby animals whose mothers received TDF. 
 
Long-term follow-up is recommended for a baby whose mother takes anti-HIV drugs 
during pregnancy. 
 
This study will follow babies born to HIV-infected mothers taking drugs in DART, to make 
sure that they remain well until the end of the DART study and to check for any side effects. 
It is extremely rare for drugs taken in pregnancy to affect babies, but we would like to 
monitor this. We would also see how many babies born to mothers taking combination anti-
HIV treatment actually become infected with HIV. In addition, we would like, if breastmilk is 
made available to us, to measure levels of anti-HIV drugs in breast milk during breast-
feeding to see if this could be helping to stop babies getting infected.  
 
What does my baby have to do in this study? 
This is an observational study. This study will not provide care related to your 
pregnancy or the delivery of your baby. Cotrimoxazole will be prescribed to your baby from 
6 weeks of age to prevent your baby getting a common chest infection (called PCP). No 
other treatment or clinical care will be provided in this study. If your baby gets ill, you will 
need to take them to your usual clinic for treatment. Any infected babies who need anti-HIV 
drugs may be enrolled into the ARROW study if they are eligible. 
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You will be asked to bring your baby to the clinic at specific visits during this 
study up until the end of the main DART study. Information will be collected at every 
visit using the prospective follow-up form and will include the following: history of 
development, length, weight, head size, any hospitalisations, HIV status when known, 
information on infant feeding and any other medication your baby has been taking. 
Retrospective information will also be collected at the enrolment visit. 
 
Blood will be taken to check whether or not your baby has got HIV at 6 weeks and 48 weeks 
and at other times if you are still breast feeding. If your baby is well, HIV antibody testing 
will be done at 72 weeks. If your baby becomes sick, a blood sample will be taken at that 
visit to check the HIV status. If he/ she has a positive HIV test result, a repeat blood sample 
will be collected at the next visit to confirm that your baby has HIV. An infant will be 
considered HIV infected after 2 positive HIV PCR DNA or RNA tests. You will receive the 
results of your baby’s tests as soon as they become available. 
  
At week 6, blood tests will be done, and then repeated at week 24, and the other follow up 
visits until the end of the study, to check how well your baby’s kidneys and liver are working 
as well as the number of red and white cells. You will receive the results of your 
baby’s tests as soon as they become available. Any leftover blood will be stored at all 
the blood draw time points for later retrospective HIV testing and resistance testing if 
required.  
 
At these visits we will take about 5mls of blood in total (approximately 1 teaspoon) from 
your baby. We will use a cream to make sure that their skin is numb to diminish pain.  
 
We would also like to collect breast milk from breast-feeding women. This is optional, and if 
agreed then approximately 15 mls of breast milk will be expressed from each breast at 2, 6, 
12 and 24 weeks after delivery (depending on when breast feeding has stopped). For 
breastfeeding mothers who enrol after their baby is born they may be asked for an optional 
sample at the enrolment visit. The breast milk will be frozen and stored for later 
antiretroviral drug levels measurements.  
 
Your baby should be brought for the study visits at the following ages: 
 
Visit week Age of baby 
2 2 weeks 
6 6 weeks 
12 12 weeks 
24 24 weeks 
48 48 weeks 
72 1 year, 20 weeks 
96 1 year, 44 weeks 
120 2 years, 16 weeks 
144 2 years, 40 weeks 
168 3 years, 12 weeks 
192 3 years, 36 weeks 
216 4 years, 8 weeks 
240 4 years, 32 weeks  
 
These visits are aimed to coincide with the mother’s visit to the DART clinic. Because the 
visits are at 24 week intervals some infants may not have been seen for up to 6months near 
the end of the DART study so we would also like to get an additional last follow up visit near 
to the end of the DART study. These will also coincide with the mothers/carers DART visit 
schedule. 
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Confidentiality 
Information about your baby will be kept confidential and will not be made available to 
anyone who is not connected to the study without your consent. 
 
Participation 
Participation in this study is entirely voluntary. If you decide that you do not wish 
your baby to take part that is entirely your right. Your decision will in no way affect any 
present or future treatment for you. 
 
What are the possible benefits and disadvantages of taking part? 
Possible disadvantages are that you will have to bring your baby to the DART clinic with you. 
Your baby will also have to have a small amount of blood drawn (approximately 1 teaspoon) 
each time. It is hoped that by following up infants born in DART long term we will be able to 
show that taking these antiretroviral drugs during pregnancy is safe. 
 
As part of this study, blood samples will be stored. These will be tested at the end of the 
study to find out how much of your drugs there are in your baby. Some tests may also look 
for HIV antibodies in your baby, but new tests are being developed all the time. We are 
therefore asking for you to agree that stored blood samples can be used in future for tests 
relevant to HIV.  
 
If you need more information about this study, please ask the doctors, nurses or counsellors 
or call: 
 
Doctor: .......................................................................... Tel: ..........................................  
 
Nurse: ............................................................................ Tel: ..........................................  
 
Counsellor: .................................................................... Tel: ..........................................  
 
Thank you for taking time to consider this study for your child. Please ask any questions and 
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Appendix 2: IFU Study Consent Form (Version 1.2) 
To be printed on headed paper 
 
FOLLOW UP OF INFANTS BORN IN DART 
STUDY CONSENT 
                            Centre:      Entebbe        Harare          JCRC           Acad All  
Child’s 
Initials 
    Date/Year 
of Birth D D M M M 2 0 Y Y
 Child’s Clinic / 
Hospital Number 




D D M M M 2 0 Y Y  Male  
Female 
 Mother’s DART 
Number 
       
 
                   DART INFANT FOLLOW UP CONSENT for PARENTS/CARER 
                                                                                                                                                         Please initial (or mark box) if you agree: 
 
Carer’s signature (or thumbprint) Print name Date 
  
D D M M M 2 0 Y Y 
Witness’s signature (or thumbprint) Print name Date 
  
D D M M M 2 0 Y Y 
Doctor’s signature Print name Date 
  
D D M M M 2 0 Y Y 
IMPORTANT: one signed original to be kept in DART Infant Follow-Up trial file by researcher, one signed copy to be 
given to carer, one signed original to be kept in the clinic notes 
I have read and understood the information sheet (version 1.2) on the DART infant follow-up 
study. The details of this study have been explained to me by Dr………………………… and my 
questions have been answered satisfactorily. 
 
I know that I can withdraw my child from the study at any time.  
I am willing to allow access to my child’s medical notes to check that the DART Infant Follow 
Up study is being carried out correctly and I understand that strict confidentiality will be 
maintained.  
 
I agree to my child’s routine blood results and clinical information being included in 
continued follow-up after the study has ended. I understand that this information will not be 
identified by either my or my child’s name. 
 
I agree that my child can take part in this study, which is following children whose mothers 
have taken combination anti-HIV therapy during pregnancy.  
I agree for small quantities of blood to be stored so that further work can be done to help 
understand more about effective prevention of HIV. I understand that these samples will not 
be identified by either my or my child’s name. 
 
Optional: 
If the child’s mother and breastfeeding, I agree to provide breastmilk samples to look at levels of 
anti-HIV drugs which my baby might be receiving but understand that this is optional and not a 
requirement for my child to enter the study. 
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Appendix 3: Toxicity Gradings 
Division of AIDS table for grading the severity of adverse events (published December 2004) apart 
from neutrophil gradings, which are based on WHO guidelines (Antiretroviral therapy for HIV infection 
in infants and children towards universal access: Recommendations for a public health approach 
(2007 Revision). World Health Organization 2007) and NIH Paediatric toxicity tables (NIH Division of 
Microbiology and Infectious Diseases (DMID) Pediatric toxicity tables, November 2007).  
 
ULN = Upper Limit of Normal ; LLN = Lower Limit of Normal  
 
CLINICAL 









ESTIMATING SEVERITY GRADE 
Clinical adverse event 
NOT identified 
elsewhere in this DAIDS 
AE grading table  
Symptoms causing no or 
minimal interference 
with usual social & 
functional activities 
Symptoms causing 
greater than minimal 
interference with usual 
social & functional 
activities 
Symptoms causing 
inability to perform usual 
social & functional 
activities 
Symptoms causing 
inability to perform basic 
self-care functions OR 
Medical or operative 
intervention indicated to 
prevent permanent 
impairment, persistent 
disability, or death  
SYSTEMIC 
Acute systemic allergic 
reaction  
Localized urticaria 
(wheals) with no 
medical intervention 
indicated 
Localized urticaria with 
medical intervention 
indicated OR Mild 
angioedema with no 
medical intervention 
indicated 
Generalized urticaria OR 
Angioedema with medical 
intervention indicated OR 
Symptomatic mild 
bronchospasm 




Chills Symptoms causing no or 
minimal interference 
with usual social & 
functional activities 
Symptoms causing 
greater than minimal 
interference with usual 
social & functional 
activities  
Symptoms causing 
inability to perform usual 





Symptoms causing no or 
minimal interference 
with usual social & 
functional activities 
Symptoms causing 
greater than minimal 
interference with usual 
social & functional 
activities 
Symptoms causing 
inability to perform usual 
social & functional 
activities 
Incapacitating fatigue/ 
malaise symptoms causing 
inability to perform basic 
self-care functions 
Fever (nonaxillary) 37.7 – 38.6°C 38.7 – 39.3°C 39.4 – 40.5°C > 40.5°C  
Pain (indicate body site) 
DO NOT use for pain 
due to injection (See 
Injection Site Reactions: 
Injection site pain) 
See also Headache, 
Arthralgia, and Myalgia 
Pain causing no or 
minimal interference 
with usual social & 
functional activities 
Pain causing greater than 
minimal interference 
with usual social & 
functional activities 
Pain causing inability to 
perform usual social & 
functional activities 
Disabling pain causing 
inability to perform basic 
self-care functions OR 
Hospitalization (other than 




NA 5 – 9% loss in body 
weight from baseline 
10 – 19% loss in body 
weight from baseline 
≥ 20% loss in body weight 
from baseline OR  
Aggressive intervention 
indicated [e.g., tube 
feeding or total parenteral 
nutrition (TPN)] 
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Infection (any other than 
HIV infection) 
Localized, no systemic 
antimicrobial treatment 
indicated AND 
Symptoms causing no or 
minimal interference 
with usual social & 
functional activities 
Systemic antimicrobial 
treatment indicated OR 
Symptoms causing 
greater than minimal 
interference with usual 
social & functional 
activities 
Systemic antimicrobial 
treatment indicated AND 
Symptoms causing 
inability to perform usual 
social & functional 
activities OR Operative 
intervention (other than 
simple incision and 
drainage) indicated 
Life-threatening 
consequences (e.g., septic 
shock) 
INJECTION SITE REACTIONS 
Injection site pain (pain 
without touching) 
Or 
Tenderness (pain when 
area is touched)  
Pain/tenderness causing 
no or minimal limitation 
of use of limb 
Pain/tenderness limiting 
use of limb OR 
Pain/tenderness causing 
greater than minimal 
interference with usual 




inability to perform usual 




inability to perform basic 
self-care function OR 
Hospitalization (other than 
emergency room visit) 
indicated for management 
of pain/tenderness 
Injection site reaction (localized) 




of 5x5 cm – 9x9 cm (or 
25 cm2 – 81cm2) 
Erythema OR Induration 
OR Edema  
> 9 cm any diameter 
(or > 81 cm2) 
Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR 
Drainage 
Necrosis (involving 
dermis and deeper tissue) 
 
Paediatric ≤ 15 
years 
Erythema OR 
Induration OR Edema 
present but ≤ 2.5 cm 
diameter 
Erythema OR Induration 
OR Edema > 2.5 cm 
diameter but < 50% 
surface area of the 
extremity segment (e.g., 
upper arm/thigh) 
Erythema OR Induration 
OR Edema involving  
≥ 50% surface area of the 
extremity segment (e.g., 
upper arm/thigh) OR 
Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR 
Drainage 
Necrosis (involving 
dermis and deeper tissue) 
Pruritis associated with 
injection  
See also Skin: Pruritis 
(itching - no skin 
lesions) 
Itching localized to 
injection site AND 
Relieved spontaneously 
or with < 48 hours 
treatment  
Itching beyond the 
injection site but not 
generalized OR Itching 
localized to injection site 
requiring ≥ 48 hours 
treatment  
Generalized itching 
causing inability to 
perform usual social & 
functional activities 
NA 
SKIN – DERMATOLOGICAL 
Alopecia Thinning detectable by 
study participant (or by 
caregiver for young 
children and disabled 
adults) 
Thinning or patchy hair 
loss detectable by health 
care provider 
Complete hair loss NA 
Cutaneous reaction – 
rash 
Localized macular rash  Diffuse macular, 
maculopapular, or 
morbilliform rash OR 
Target lesions  
Diffuse macular, 
maculopapular, or 
morbilliform rash with 
vesicles or limited number 
of bullae OR Superficial 
ulcerations of mucous 
membrane limited to one 
site 
Extensive or generalized 
bullous lesions OR 
Stevens-Johnson syndrome 
OR Ulceration of mucous 
membrane involving two 
or more distinct mucosal 
sites OR Toxic epidermal 
necrolysis (TEN) 
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Hyperpigmentation Slight or localized Marked or generalized NA NA 
Hypopigmentation Slight or localized  Marked or generalized NA NA 
Pruritis (itching – no 
skin lesions)  




Itching causing no or 
minimal interference 
with usual social & 
functional activities 
Itching causing greater 
than minimal 
interference with usual 
social & functional 
activities 
Itching causing inability to 
perform usual social & 






(By ECG or physical 
exam) 








intervention indicated  
Life-threatening 




NA NA Symptomatic ischemia 
(stable angina) OR Testing 
consistent with ischemia  
Unstable angina OR Acute 
myocardial infarction 
Hemorrhage (significant 
acute blood loss) 
NA Symptomatic AND No 
transfusion indicated 
Symptomatic AND 
Transfusion of ≤ 2 units 
packed RBCs (for children 
≤ 10 cc/kg) indicated  
Life-threatening 
hypotension OR 
Transfusion of > 2 units 
packed RBCs (for children 
> 10 cc/kg) indicated 
Hypertension 
Adult > 17 years 
(with repeat testing 
at same visit) 
 
> 140 – 159 mmHg 
systolic 
OR 
> 90 – 99 mmHg 
diastolic 
> 160 – 179 mmHg 
systolic 
OR 
> 100 – 109 mmHg 
diastolic 
 
> 180 mmHg systolic 
OR 






indicated (other than 
emergency room visit) 
Paediatric ≤ 17 
years 
(with repeat testing 
at same visit) 
 
NA 91st –  94th percentile 
adjusted for age, height, 
and gender (systolic 
and/or diastolic) 
≥ 95th percentile adjusted 
for age, height, and gender 





indicated (other than 
emergency room visit) 
Hypotension NA Symptomatic, corrected 
with oral fluid 
replacement 
Symptomatic, IV fluids 
indicated 
Shock requiring use of 
vasopressors or 
mechanical assistance to 
maintain blood pressure 
 
Pericardial effusion Asymptomatic, small 




or larger effusion 
requiring no intervention 
 
Effusion with non-life 
threatening physiologic 





tamponade) OR Urgent 
intervention indicated 
Prolonged PR interval 
 Adult > 16 years PR interval  
0.21 – 0.25 sec 
PR interval 
> 0.25 sec 
Type II 2nd degree AV 
block OR Ventricular 
pause > 3.0 sec 
Complete AV block  
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 Paediatric ≤ 16 
years 
1st degree AV block 
(PR > normal for age 
and rate) 
Type I 2nd degree AV 
block  
Type II 2nd degree AV 
block  
Complete AV block 
Prolonged QTc 
Adult > 16 years 
 
Asymptomatic, QTc 
interval 0.45 – 0.47 sec 
OR Increase interval < 
0.03 sec above baseline 
Asymptomatic, QTc 
interval 0.48 – 0.49 sec 
OR Increase in interval 
0.03 – 0.05 sec above 
baseline 
Asymptomatic, QTc 
interval ≥ 0.50 sec OR 
Increase in interval  
≥ 0.06 sec above baseline 
Life-threatening 
consequences, e.g. Torsade 
de pointes or other 
associated serious 
ventricular dysrhythmia 
Paediatric ≤ 16 
years 
Asymptomatic, QTc 
interval 0.450 –  
0.464 sec  
Asymptomatic, QTc 
interval 0.465 –  
0.479 sec  
Asymptomatic, QTc 
interval ≥ 0.480 sec  
Life-threatening 
consequences, e.g.  
Torsade de pointes  or 
other associated serious 
ventricular dysrhythmia 
Thrombosis/embolism NA Deep vein thrombosis 









filter, invasive procedure)  
Embolic event (e.g., 
pulmonary embolism, life-
threatening thrombus)  
Vasovagal episode 
(associated with a 
procedure of any kind) 
Present without loss of 
consciousness  
Present with transient 
loss of consciousness 
NA  NA 
Ventricular dysfunction 
(congestive heart failure) 
NA Asymptomatic 
diagnostic finding AND 
intervention indicated 





congestive heart failure 
GASTROINTESTINAL 
Anorexia Loss of appetite without 
decreased oral intake 
 
Loss of appetite 
associated with 
decreased oral intake 
without significant 
weight loss  
 
Loss of appetite associated 





indicated [e.g., tube 
feeding or total parenteral 
nutrition (TPN)] 
Ascites Asymptomatic Symptomatic AND 
Intervention indicated 














consequences (e.g., sepsis 
or perforation)  
Constipation  NA Persistent constipation 
requiring regular use of 
dietary modifications, 
laxatives, or enemas  







Paediatric ≥ 1 year 
Transient or intermittent 
episodes of unformed 
stools OR Increase of ≤ 
3 stools over baseline 
per 24-hour period 
Persistent episodes of 
unformed to watery 
stools OR Increase of 4 
– 6 stools over baseline 
per 24-hour period 
Bloody diarrhea OR 
Increase of ≥ 7 stools per 
24-hour period OR IV 
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Paediatric < 1 year Liquid stools (more 
unformed than usual) 
but usual number of 
stools 
Liquid stools with 
increased number of 
stools OR Mild 
dehydration 
Liquid stools with 
moderate dehydration 
Liquid stools resulting in 
severe dehydration with 
aggressive rehydration 
indicated OR Hypotensive 
shock 
Dysphagia-Odynophagia  Symptomatic but able to 
eat usual diet 
Symptoms causing 




severely altered dietary 
intake with medical 
intervention indicated 
Life-threatening reduction 
in oral intake 
Mucositis/stomatitis  
(clinical exam) 
Indicate site (e.g., 
larynx, oral) 










ulcerations OR Mucosal 
bleeding with minor 
trauma 
Tissue necrosis OR 
Diffuse spontaneous 




Nausea  Transient (< 24 hours) 
or intermittent nausea 
with no or minimal 
interference with oral 
intake 
Persistent nausea 
resulting in decreased 
oral intake for 24 – 48 
hours 
Persistent nausea resulting 
in minimal oral intake for 
> 48 hours OR Aggressive 





Pancreatitis NA Symptomatic AND 
Hospitalization not 
indicated (other than 
emergency room visit) 
Symptomatic AND 
Hospitalization indicated 










for clinical exam 
 
 





greater than minimal 
interference with usual 
social & functional 
activities OR Medical 
intervention indicated  
Symptoms causing 
inability to perform usual 
social & functional 
activities OR Operative 





Vomiting Transient or intermittent 
vomiting with no or 
minimal interference 
with oral intake 
Frequent episodes of 
vomiting with no or mild 
dehydration 
Persistent vomiting 
resulting in orthostatic 
hypotension OR 
Aggressive rehydration 







in mood (e.g., agitation, 
anxiety, depression, 
mania, psychosis) 
Alteration causing no or 
minimal interference 
with usual social & 
functional activities  
Alteration causing 
greater than minimal 
interference with usual 
social & functional 
activities  
Alteration causing 
inability to perform usual 
social & functional 
activities  
Behavior potentially 
harmful to self or others 
(e.g., suicidal and 
homicidal ideation or 
attempt, acute psychosis) 
OR Causing inability to 
perform basic self-care 
functions  
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Altered Mental Status  




dementia and attention 
deficit disorder) 
Changes causing no or 
minimal interference 
with usual social & 
functional activities 
Mild lethargy or 
somnolence causing 
greater than minimal 
interference with usual 
social & functional 
activities 
Confusion, memory 
impairment, lethargy, or 
somnolence causing 
inability to perform usual 
social & functional 
activities 
Delirium OR obtundation, 
OR coma 
Ataxia  Asymptomatic ataxia 
detectable on exam OR 
Minimal ataxia causing 
no or minimal 
interference with usual 
social & functional 
activities 
Symptomatic ataxia 
causing greater than 
minimal interference 
with usual social & 
functional activities 
Symptomatic ataxia 
causing inability to 
perform usual social & 
functional activities  
Disabling ataxia causing 





dementia and attention 
deficit disorder)  
Disability causing no or 
minimal interference 
with usual social & 




greater than minimal 
interference with usual 
social & functional 
activities OR Specialized 
resources on part-time 
basis indicated 
Disability causing inability 
to perform usual social & 
functional activities OR 
Specialized resources on a 
full-time basis indicated 
Disability causing inability 






NA NA Transient ischemic attack Cerebral vascular accident 
(CVA, stroke) with 
neurological deficit  
Developmental delay – 
Paediatric ≤ 16 years 
Mild developmental 
delay, either motor or 
cognitive, as determined 
by comparison with a 
developmental 
screening tool 
appropriate for the 
setting  
Moderate developmental 
delay,  either motor or 
cognitive, as determined 
by comparison with a 
developmental screening 
tool appropriate for the 
setting  
Severe developmental 
delay, either motor or 
cognitive, as determined 
by comparison with a 
developmental screening 
tool appropriate for the 
setting  
Developmental regression, 
either motor or cognitive, 
as determined by 
comparison with a 
developmental screening 
tool appropriate for the 
setting 
Headache  Symptoms causing no or 
minimal interference 
with usual social & 
functional activities 
Symptoms causing 
greater than minimal 
interference with usual 
social & functional 
activities 
Symptoms causing 
inability to perform usual 
social & functional 
activities 
Symptoms causing 
inability to perform basic 
self-care functions OR 
Hospitalization indicated 
(other than emergency 
room visit) OR Headache 
with significant 
impairment of alertness or 
other neurologic function  
Insomnia NA Difficulty sleeping 
causing greater than 
minimal interference 
with usual social & 
functional activities 
Difficulty sleeping causing 
inability to perform usual 
social & functional 
activities 
Disabling insomnia 
causing inability to 




(including myopathy & 
neuropathy)  
Asymptomatic with 
decreased strength on 
exam OR Minimal 
muscle weakness 
causing no or minimal 
interference with usual 
social & functional 
activities 
Muscle weakness 
causing greater than 
minimal interference 
with usual social & 
functional activities 
Muscle weakness causing 
inability to perform usual 
social & functional 
activities  
Disabling muscle 
weakness causing inability 
to perform basic self-care 
functions OR Respiratory 
muscle weakness 
impairing ventilation 
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and painful neuropathy) 
Asymptomatic with 
sensory alteration on 
exam or minimal 
paresthesia causing no 
or minimal interference 
with usual social & 
functional activities  
Sensory alteration or 
paresthesia causing 
greater than minimal 
interference with usual 
social & functional 
activities  
Sensory alteration or 
paresthesia causing 
inability to perform usual 
social & functional 
activities 
Disabling sensory 
alteration or paresthesia 
causing inability to 
perform basic self-care 
functions 
 
Seizure: (new onset)  – 
Adult ≥ 18 years 
See also Seizure: 
(known pre-existing 
seizure disorder) 
NA 1 seizure  2 – 4 seizures  Seizures of any kind which 
are prolonged, repetitive 
(e.g., status epilepticus), or 





– Adult ≥ 18 years 
For worsening of 
existing epilepsy the 
grades should be based 
on an increase from 
previous level of control 
to any of these levels. 
NA Increased frequency of 
pre-existing seizures 
(non-repetitive) without 
change in seizure 
character OR Infrequent 
break-through seizures 
while on stable 
medication in a 
previously controlled 
seizure disorder 
Change in seizure 
character from baseline 
either in duration or 
quality (e.g., severity or  
focality)  
Seizures of any kind which 
are prolonged, repetitive 
(e.g., status epilepticus), or 
difficult to control (e.g., 
refractory epilepsy) 
Seizure  
– Paediatric < 18 years 
Seizure, generalized 
onset with or without 
secondary 
generalization, lasting < 
5 minutes with < 24 
hours post ictal state 
Seizure, generalized 
onset with or without 
secondary 
generalization, lasting 5 
– 20 minutes with  
< 24 hours post ictal 
state 
Seizure, generalized onset 
with or without secondary 
generalization, lasting  
> 20 minutes  
Seizure, generalized onset 
with or without secondary 
generalization, requiring 
intubation and sedation 
Syncope (not associated 
with a procedure) 
NA Present NA NA 
Vertigo Vertigo causing no or 
minimal interference 
with usual social & 
functional activities 
Vertigo causing greater 
than minimal 
interference with usual 
social & functional 
activities  
Vertigo causing inability 
to perform usual social & 
functional activities 
Disabling vertigo causing 
inability to perform basic 
self-care functions 
RESPIRATORY 
Bronchospasm (acute) FEV1 or peak flow 
reduced to  
70 – 80% 
FEV1 or peak flow  
50 – 69% 
FEV1 or peak flow  
25 – 49%  
Cyanosis OR FEV1 or 
peak flow < 25% OR 
Intubation 
Dyspnea or respiratory distress 
Adult ≥ 14 years Dyspnea on exertion 
with no or minimal 
interference with usual 
social & functional 
activities  
Dyspnea on exertion 
causing greater than 
minimal interference 
with usual social & 
functional activities  
Dyspnea at rest causing 
inability to perform usual 
social & functional 
activities  
Respiratory failure with 
ventilatory support 
indicated 
Paediatric < 14 
years 
Wheezing OR minimal 
increase in respiratory 
rate for age 
Nasal flaring OR 
Intercostal retractions 
OR Pulse oximetry 90 – 
95% 
Dyspnea at rest causing 
inability to perform usual 
social & functional 
activities OR Pulse 
oximetry < 90% 
Respiratory failure with 
ventilatory support 
indicated 
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See also Arthritis 
Joint pain causing no or 
minimal interference 
with usual social & 
functional activities 
Joint pain causing 
greater than minimal 
interference with usual 
social & functional 
activities 
Joint pain causing inability 
to perform usual social & 
functional activities 
Disabling joint pain 
causing inability to 
perform basic self-care 
functions 
Arthritis 
See also Arthralgia 
Stiffness or joint 
swelling causing no or 
minimal interference 
with usual social & 
functional activities 
Stiffness or joint 
swelling causing greater 
than minimal 
interference with usual 
social & functional 
activities 
Stiffness or joint swelling 
causing inability to 
perform usual social & 
functional activities 
Disabling joint stiffness or 
swelling causing inability 
to perform basic self-care 
functions  
Bone Mineral Loss 
Adult ≥ 21 years BMD t-score  
-2.5 to -1.0  
BMD t-score < -2.5 Pathological fracture 
(including loss of vertebral 
height) 
Pathologic fracture causing 
life-threatening 
consequences  
Paediatric < 21 
years 
BMD z-score  
-2.5 to -1.0 
BMD z-score < -2.5 Pathological fracture 
(including loss of vertebral 
height) 





Muscle pain causing no 
or minimal interference 
with usual social & 
functional activities 
Muscle pain causing 
greater than minimal 
interference with usual 
social & functional 
activities 
Muscle pain causing 
inability to perform usual 
social & functional 
activities 
Disabling muscle pain 
causing inability to 
perform basic self-care 
functions 
Osteonecrosis NA Asymptomatic with 
radiographic findings 
AND No operative 
intervention indicated 
Symptomatic bone pain 
with radiographic findings 
OR Operative intervention 
indicated 
Disabling bone pain with 
radiographic findings 
causing inability to 





(For use in studies 
evaluating topical  study 
agents)  
For other cervicitis see 
Infection: Infection (any 
other than HIV 
infection)  
 
Symptoms causing no or 
minimal interference 
with usual social & 
functional activities  
Symptoms causing 
greater than minimal 
interference with usual 
social & functional 
activities  
Symptoms causing 
inability to perform usual 




inability to perform basic 
self-care functions  
Cervicitis  
(clinical exam) 
(For use in studies 
evaluating topical  study 
agents)  
For other cervicitis see 
Infection: Infection (any 







or friability) OR 
Epithelial disruption  





or friability) OR 
Epithelial disruption of 





or friability) OR Epithelial 
disruption  
50 – 75% total surface 
Epithelial disruption  
> 75% total surface 
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Spotting observed by 
participant OR Minimal 
blood observed during 
clinical or colposcopic 
examination 
Inter-menstrual bleeding 
not greater in duration or 
amount than usual 
menstrual cycle 
Inter-menstrual bleeding 
greater in duration or 




OR Operative intervention 
indicated 
Urinary tract obstruction 
(e.g., stone) 
NA Signs or symptoms of 
urinary tract obstruction 
without  hydronephrosis 
or renal dysfunction 
Signs or symptoms of 
urinary tract obstruction 






(Use in studies 
evaluating topical study 
agents)  
For other vulvovaginitis 
see Infection: Infection 
(any other than HIV 
infection) 
 
Symptoms causing no or 
minimal interference 
with usual social & 
functional activities  
Symptoms causing 
greater than minimal 
interference with usual 
social & functional 
activities  
Symptoms causing 
inability to perform usual 




inability to perform basic 
self-care functions  
Vulvovaginitis  
(clinical exam) 
(Use in studies 
evaluating topical study 
agents)  
For other vulvovaginitis 
see Infection: Infection 






Epithelial disruption  




Epithelial disruption of 
25 - 49% total surface 
Severe vaginal 
abnormalities on 
examination OR Epithelial 
disruption  
50 - 75% total surface 
Vaginal perforation OR 
Epithelial disruption 
> 75% total surface 
OCULAR/VISUAL 
Uveitis Asymptomatic but 
detectable on exam 
Symptomatic anterior 
uveitis OR Medical 
intervention indicated 
Posterior or pan-uveitis 
OR Operative intervention 
indicated 
 
Disabling visual loss in 
affected eye(s)  
Visual changes (from 
baseline) 
Visual changes causing 
no or minimal 
interference with usual 
social & functional 
activities 
Visual changes causing 
greater than minimal 
interference with usual 
social & functional 
activities 
Visual changes causing 
inability to perform usual 
social & functional 
activities 







(e.g., back of neck, 
breasts, abdomen) 
Detectable by study 
participant (or by 
caregiver for young 
children and disabled 
adults) 
Detectable on physical 
exam by health care 
provider 
Disfiguring OR Obvious 
changes on casual visual 
inspection 
NA 
Diabetes mellitus NA New onset without need 
to initiate medication OR 
Modification of current 
medications to regain 
glucose control 
New onset with initiation 
of medication indicated 






non-ketotic coma)  
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Gynecomastia Detectable by study 
participant or caregiver 
(for young children and 
disabled adults) 
Detectable on physical 
exam by health care 
provider 
Disfiguring OR Obvious 
on casual visual inspection 
NA 
Hyperthyroidism  Asymptomatic 
 
Symptomatic causing 
greater than minimal 
interference with usual 
social & functional 




inability to perform usual 
social & functional 




consequences (e.g., thyroid 
storm) 
Hypothyroidism Asymptomatic Symptomatic causing 
greater than minimal 
interference with usual 
social & functional 




inability to perform usual 
social & functional 







(e.g., fat loss from the 
face, extremities, 
buttocks) 
Detectable by study 
participant (or by 
caregiver for young 
children and disabled 
adults) 
Detectable on physical 
exam by health care 
provider 
Disfiguring OR Obvious 
on casual visual inspection 
NA 
 LABORATORY 









HAEMATOLOGY  Standard International Units are listed in italics 
Absolute CD4+ count  
– Adult and Paediatric  
> 13 years 
(HIV NEGATIVE 
ONLY) 
300 – 400/mm3 
300 – 400/µL 
200 –  299/mm3 
200 – 299/µL 
100 – 199/mm3 





– Adult and Paediatric  
> 13 years 
(HIV NEGATIVE 
ONLY) 
600 – 650/mm3 
0.600 x 109 – 
0.650 x 109/L 
500 – 599/mm3 
0.500 x 109 –  
0.599 x 109/L 
350 – 499/mm3 
0.350 x 109 –   
0.499 x 109/L 
< 350/mm3 
< 0.350 x 109/L 
Absolute neutrophil count (ANC) [9, 44] 
Adult and 
Paediatric,  
> 7 days 
750 –< 1,000/mm3 
0.75 x 109 – 
<1.0. x 109/L 
500 – 749/mm3 
0.5  x 109 –  
0.749 x 109/L 
250 – 499/mm3 
0.25  x 109 –  
0.499 x 109/L   
< 250/mm3 
< 0.250 x 109/L 
 Infant∗†, 2 – ≤ 7 
days 
1,250 – 1,500/mm3 
1.250  x 109 –  
1.500 x 109/L 
1,000 – 1,249/mm3 
1.000 x 109 –  
1.249 x 109/L 
750 – 999/mm3 
0.750  x 109 –  
0.999  x 109/L 
< 750/mm3 
< 0.750 x 109/L 
 Infant∗†, 1 day 4,000 – 5,000/mm3 
4.000 x 109 –  
5.000 x 109/L 
3,000 – 3,999/mm3 
3.000 x 109 –  
3.999 x109/L 
1,500 – 2,999/mm3 
1.500 x 109 –  
2.999 x 109/L 
< 1,500/mm3 
< 1.500 x 109/L 
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Fibrinogen, decreased 100 – 200 mg/dL 
1.00 – 2.00 g/L 
OR 
0.75 – 0.99 x LLN 
75 – 99 mg/dL 
0.75 – 0.99 g/L 
OR 
0.50 – 0.74 x LLN 
50 – 74 mg/dL 
0.50 – 0.74 g/L 
OR 
0.25 – 0.49 x LLN 
< 50 mg/dL  
< 0.50 g/L 
OR 
< 0.25 x LLN 
OR  





≥ 57 days  
(HIV POSITIVE 
ONLY) 
8.5 – 10.0 g/dL 
1.32 – 1.55 mmol/L 
7.5 – 8.4 g/dL 
1.16 – 1.31 mmol/L 
6.50 – 7.4 g/dL 
1.01 – 1.15 mmol/L 
< 6.5 g/dL 
< 1.01 mmol/L 
Adult and 
Paediatric  
≥ 57 days  
(HIV NEGATIVE 
ONLY)  
10.0 – 10.9 g/dL 
1.55 – 1.69 mmol/L 
OR 
Any decrease  
2.5 – 3.4 g/dL 
0.39 – 0.53 mmol/L 
9.0 – 9.9 g/dL 
1.40 – 1.54 mmol/L 
OR 
Any decrease  
3.5 – 4.4 g/dL 
0.54 – 0.68 mmol/L 
7.0 – 8.9 g/dL 
1.09 – 1.39 mmol/L 
OR 
Any decrease  
≥ 4.5 g/dL 
≥ 0.69 mmol/L 
< 7.0 g/dL 
< 1.09 mmol/L 
 




8.5 – 9.4 g/dL 
1.32 – 1.46 mmol/L 
7.0 –  8.4 g/dL 
1.09 – 1.31 mmol/L 
6.0 – 6.9 g/dL 
0.93 – 1.08 mmol/L 
< 6.00 g/dL 
< 0.93 mmol/L 




9.5 – 10.5 g/dL 
1.47 – 1.63 mmol/L 
8.0 – 9.4 g/dL 
1.24 – 1.46 mmol/L 
7.0 – 7.9 g/dL 
1.09 – 1.23 mmol/L 
< 7.00 g/dL 
< 1.09 mmol/L 




12.0 – 13.0 g/dL 
1.86 – 2.02 mmol/L 
10.0 – 11.9 g/dL 
1.55 – 1.85 mmol/L 
9.0 – 9.9 g/dL 
1.40 – 1.54 mmol/L 
< 9.0 g/dL 
< 1.40 mmol/L 
International 
Normalized Ratio of 
prothrombin time (INR) 
1.1 – 1.5 x ULN 1.6 – 2.0 x ULN 2.1 – 3.0 x ULN > 3.0 x ULN 
Methemoglobin 5.0 – 10.0% 10.1 – 15.0% 15.1 – 20.0% > 20.0% 
Prothrombin Time (PT) 1.1 – 1.25 x ULN 1.26 – 1.50 x ULN 1.51 – 3.00 x ULN > 3.00 x ULN 
Partial Thromboplastin 
Time (PTT) 
1.1 – 1.66 x ULN 1.67 – 2.33 x ULN 2.34 – 3.00 x ULN > 3.00 x ULN 
Platelets, decreased 100,000 –  
124,999/mm3 
100.000 x 109 – 
124.999 x 109/L 
50,000 –  
99,999/mm3 
50.000 x 109 – 
99.999 x 109/L 
25,000 –  
49,999/mm3 
25.000 x 109 – 
49.999 x 109/L 
< 25,000/mm3 
< 25.000 x 109/L 
WBC, decreased 2,000 – 2,500/mm3 
2.000 x 109 –  
2.500 x 109/L 
1,500 – 1,999/mm3 
1.500 x 109 –  
1.999 x 109/L 
1,000 – 1,499/mm3 
1.000 x 109 –  
1.499 x 109/L 
< 1,000/mm3 
< 1.000 x 109/L 
CHEMISTRIES  Standard International Units are listed in italics  
Acidosis NA pH < normal, but ≥ 7.3 pH < 7.3 without life-
threatening consequences 
pH < 7.3 with life-
threatening consequences 
Albumin, serum, low 3.0 g/dL – < LLN 
30 g/L – < LLN 
2.0 – 2.9 g/dL 
20 – 29 g/L 
< 2.0 g/dL 
< 20 g/L 
NA 
Alkaline Phosphatase 1.25 – 2.5 x ULN† 2.6 – 5.0 x ULN† 5.1 – 10.0 x ULN† > 10.0 x ULN† 
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Alkalosis NA pH > normal, but ≤ 7.5 pH > 7.5 without life-
threatening consequences 
pH > 7.5 with life-
threatening consequences  
ALT (SGPT) 1.25 – 2.5 x ULN 2.6 – 5.0 x ULN 5.1 – 10.0 x ULN > 10.0 x ULN 
AST (SGOT) 1.25 – 2.5 x ULN 2.6 – 5.0 x ULN 5.1 – 10.0 x ULN > 10.0 x ULN 
Bicarbonate, serum, low 16.0 mEq/L – < LLN 
16.0 mmol/L – < LLN 
11.0 – 15.9 mEq/L 
11.0 – 15.9 mmol/L 
8.0 – 10.9 mEq/L 
8.0 – 10.9 mmol/L 
< 8.0 mEq/L 
< 8.0 mmol/L 
Bilirubin (Total) 
Adult and 
Paediatric > 14 
days 
1.1 – 1.5 x ULN 1.6 – 2.5 x ULN 2.6 – 5.0 x ULN > 5.0 x ULN 
Infant∗†, ≤ 14 days 
(non-hemolytic) 
NA 20.0 – 25.0 mg/dL 
342 – 428 µmol/L 
25.1 – 30.0 mg/dL 
429 – 513 µmol/L 
> 30.0 mg/dL 
> 513.0 µmol/L 
Infant∗†, ≤ 14 days 
(hemolytic) 
NA NA 20.0 – 25.0 mg/dL 
342 – 428 µmol/L 
> 25.0 mg/dL 
> 428 µmol/L 
Calcium, serum, high (corrected for albumin) 
Adult and 
Paediatric  
≥ 7 days 
10.6  – 11.5 mg/dL 
2.65 – 2.88 mmol/L 
11.6  – 12.5 mg/dL 
2.89 – 3.13 mmol/L 
12.6  – 13.5 mg/dL 
3.14 – 3.38 mmol/L 
> 13.5 mg/dL 
> 3.38 mmol/L 
Infant∗†, < 7 days 11.5 – 12.4 mg/dL 
2.88 – 3.10 mmol/L 
12.5 – 12.9 mg/dL 
3.11 – 3.23 mmol/L 
13.0 – 13.5 mg/dL 
3.245 – 3.38 mmol/L 
> 13.5 mg/dL 
> 3.38 mmol/L 
Calcium, serum, low (corrected for albumin) 
Adult and 
Paediatric  
≥ 7 days  
7.8  – 8.4 mg/dL 
1.95 – 2.10 mmol/L 
7.0  – 7.7 mg/dL 
1.75 – 1.94 mmol/L 
6.1  – 6.9 mg/dL 
1.53 – 1.74 mmol/L 
< 6.1 mg/dL 
< 1.53 mmol/L 
Infant∗†, < 7 days 6.5 – 7.5 mg/dL 
1.63 – 1.88 mmol/L 
6.0 – 6.4 mg/dL 
1.50 – 1.62 mmol/L 
5.50 – 5.90 mg/dL 
1.38 – 1.51 mmol/L 
< 5.50 mg/dL 
< 1.38 mmol/L 
Cardiac troponin I 
(cTnI) 
NA NA NA Levels consistent with 
myocardial infarction or 
unstable angina as defined 
by the manufacturer 
Cardiac troponin T 
(cTnT) 
NA NA NA ≥ 0.20 ng/mL 
OR 
Levels consistent with 
myocardial infarction or 
unstable angina as defined 
by the manufacturer 
Cholesterol (fasting) 
Adult ≥ 18 years 200 – 239 mg/dL 
5.18 – 6.19 mmol/L 
240 – 300 mg/dL 
6.20 – 7.77 mmol/L 
> 300 mg/dL 
> 7.77 mmol/L 
NA 
Paediatric < 18 
years 
170 – 199 mg/dL 
4.40 – 5.15 mmol/L 
200 – 300 mg/dL 
5.16 – 7.77 mmol/L 
> 300 mg/dL 
> 7.77 mmol/L 
NA 
Creatine Kinase 3.0 – 5.9 x ULN† 6.0 – 9.9 x ULN† 10.0 – 19.9 x ULN† ≥ 20.0 x ULN† 
Creatinine 1.1 – 1.3 x ULN† 1.4 – 1.8 x ULN† 1.9 – 3.4 x ULN† ≥ 3.5 x ULN† 
Glucose, serum, high  
 Nonfasting 116 – 160 mg/dL 
6.44 – 8.88 mmol/L 
161 – 250 mg/dL 
8.89 – 13.88 mmol/L 
251 – 500 mg/dL 
13.89 – 27.75 mmol/L 
> 500 mg/dL 
> 27.75 mmol/L 
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   Fasting 110 – 125 mg/dL 
6.11 – 6.94 mmol/L 
126 – 250 mg/dL 
6.95 – 13.88 mmol/L 
251 – 500 mg/dL 
13.89 – 27.75 mmol/L 
> 500 mg/dL 
> 27.75 mmol/L 
Glucose, serum, low  
Adult and 
Paediatric  
≥ 1 month 
55 – 64 mg/dL 
3.05 – 3.55 mmol/L 
40 – 54 mg/dL 
2.22 – 3.06 mmol/L 
30 – 39 mg/dL 
1.67 – 2.23 mmol/L 
< 30 mg/dL 
< 1.67 mmol/L 
Infant∗†, < 1 month 50 – 54 mg/dL 
2.78 – 3.00 mmol/L 
40 – 49 mg/dL 
2.22 – 2.77 mmol/L 
30 – 39 mg/dL 
1.67 – 2.21 mmol/L 
< 30 mg/dL 
< 1.67 mmol/L 
Lactate < 2.0 x ULN without 
acidosis 
≥ 2.0 x ULN without 
acidosis 
Increased lactate with pH 
< 7.3 without life-
threatening consequences  
Increased lactate with pH < 
7.3 with life-threatening 
consequences  
LDL cholesterol (fasting) 
Adult ≥ 18 years 130 – 159 mg/dL 
3.37 – 4.12 mmol/L 
160 – 190 mg/dL 
4.13 – 4.90 mmol/L 
≥ 190 mg/dL 
≥ 4.91 mmol/L 
NA 
Paediatric > 2 - < 
18 years 
110 – 129 mg/dL  
2.85 – 3.34 mmol/L 
130 – 189 mg/dL 
3.35 – 4.90 mmol/L 
≥ 190 mg/dL 
≥ 4.91 mmol/L 
NA 
Lipase 1.1 – 1.5 x ULN 1.6 – 3.0 x ULN 3.1 – 5.0 x ULN > 5.0 x ULN 
Magnesium, serum, low 1.2  – 1.4 mEq/L 
0.60 – 0.70 mmol/L 
0.9 – 1.1 mEq/L 
0.45 – 0.59 mmol/L 
0.6 – 0.8 mEq/L 
0.30 – 0.44 mmol/L 
< 0.60 mEq/L 
< 0.30 mmol/L 
Pancreatic amylase 1.1 – 1.5 x ULN 1.6 – 2.0 x ULN 2.1 – 5.0 x ULN > 5.0 x ULN 
Phosphate, serum, low 
Adult and 
Paediatric  
> 14 years 
2.5 mg/dL – < LLN 
0.81 mmol/L – < LLN 
2.0 – 2.4 mg/dL 
0.65 – 0.80 mmol/L 
1.0 – 1.9 mg/dL 
0.32 – 0.64 mmol/L 
< 1.00 mg/dL 
< 0.32 mmol/L 
Paediatric 1 year – 
14 years  
3.0 – 3.5 mg/dL 
0.97 – 1.13 mmol/L 
2.5 – 2.9 mg/dL 
0.81 – 0.96 mmol/L 
1.5 – 2.4 mg/dL 
0.48 – 0.80 mmol/L 
< 1.50 mg/dL 
< 0.48 mmol/L 
Paediatric < 1 year 3.5 – 4.5 mg/dL 
1.13 – 1.45 mmol/L 
2.5 – 3.4 mg/dL 
0.81 – 1.12 mmol/L 
1.5 – 2.4 mg/dL 
0.48 – 0.80 mmol/L 
< 1.50 mg/dL 
< 0.48 mmol/L 
Potassium, serum, high 5.6 – 6.0 mEq/L 
5.6 – 6.0 mmol/L 
6.1 – 6.5 mEq/L 
6.1 – 6.5 mmol/L 
6.6 – 7.0 mEq/L 
6.6 – 7.0 mmol/L 
> 7.0 mEq/L 
> 7.0 mmol/L 
Potassium, serum, low 3.0 – 3.4 mEq/L 
3.0 – 3.4 mmol/L 
2.5 – 2.9 mEq/L 
2.5 – 2.9 mmol/L 
2.0 – 2.4 mEq/L 
2.0 – 2.4 mmol/L 
< 2.0 mEq/L 
< 2.0 mmol/L 
Sodium, serum, high 146 – 150 mEq/L 
146 – 150 mmol/L 
151 – 154 mEq/L 
151 – 154 mmol/L 
155 – 159 mEq/L 
155 – 159 mmol/L 
≥ 160 mEq/L 
≥ 160 mmol/L 
Sodium, serum, low 130 – 135 mEq/L 
130 – 135 mmol/L 
125 – 129 mEq/L 
125 – 129 mmol/L 
121 – 124 mEq/L 
121 – 124 mmol/L 
≤ 120 mEq/L 
≤ 120 mmol/L 
Triglycerides (fasting) NA 500 – 750 mg/dL 
5.65 – 8.48 mmol/L 
751 – 1,200 mg/dL 
8.49 – 13.56 mmol/L 
> 1,200 mg/dL 
> 13.56 mmol/L 
Uric acid 7.5 – 10.0 mg/dL 
0.45 – 0.59 mmol/L 
10.1 – 12.0 mg/dL 
0.60 – 0.71 mmol/L 
12.1 – 15.0 mg/dL 
0.72 – 0.89 mmol/L 
> 15.0 mg/dL 
> 0.89 mmol/L 
URINALYSIS  Standard International Units are listed in italics 
Hematuria 
(microscopic) 
 6 – 10 RBC/HPF > 10 RBC/HPF Gross, with or without 




1 + 2 – 3 + 4 + NA 
Proteinuria, 24 hour collection 
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≥ 10 years 
200 – 999 mg/24 h 
0.200 – 0.999 g/d 
1,000 – 1,999 mg/24 h 
1.000 – 1.999 g/d 
2,000 – 3,500 mg/24 h 
2.000 – 3.500 g/d 
> 3,500 mg/24 h 
> 3.500 g/d 
Paediatric > 3 mo -  
< 10 years 
201 – 499 mg/m2/24 h 
0.201 – 0.499 g/d 
500 – 799 mg/m2/24 h 
0.500 – 0.799 g/d 
800 – 1,000  
mg/m2/24 h 
0.800 – 1.000 g/d 
> 1,000 mg/ m2/24 h 
> 1.000 g/d 
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Appendix 4: WHO Staging  
 
Paediatric WHO clinical staging for HIV/AIDS for infants and children with established 
HIV infection1 
Clinical Stage 1 
 
Asymptomatic  
Persistent generalized lymphadenopathy  
 
Clinical Stage 2 
 
Unexplained persistent hepatosplenomegaly  
Papular pruritic eruptions 
Extensive wart virus infection  
Extensive molluscum contagiosum  
Recurrent oral ulcerations  
Unexplained persistent parotid enlargement 
Lineal gingival erythema  
Herpes zoster   
Recurrent or chronic respiratory tract infections (otitis media, otorrhoea, sinusitis or tonsillitis)  
Fungal nail infections 
 
Clinical Stage 3 
 
Unexplained moderate malnutrition not adequately responding to standard therapy  
Unexplained persistent diarrhoea (14 days or more) 
Unexplained persistent fever (above 37.5 oC intermittent or constant, for longer than one month) 
Persistent oral candidiasis (after first 6- 8 weeks of life) 
Oral hairy leukoplakia 
Acute necrotizing ulcerative gingivitis or periodontitis  
Lymph node tuberculosis 
Pulmonary tuberculosis 
Severe recurrent bacterial pneumonia  
Symptomatic lymphoid interstitial pneumonitis 
Chronic HIV-associated lung disease including brochiectasis 
Unexplained anaemia (<8g/dl ), neutropenia (<500/mm3) and/or chronic thrombocytopenia (<50 000/ mm3)  
 
Clinical Stage 4 
 
Unexplained severe wasting, stunting or severe malnutrition not responding to standard therapy 
Pneumocystis pneumonia 
Recurrent severe presumed bacterial infections (e.g. empyema, pyomyositis, bone or joint infection, meningitis, 
but excluding pneumonia) 
Chronic herpes simplex infection (orolabial or cutaneous of more than one month's duration or visceral at any 
site)  
Extrapulmonary tuberculosis  
Kaposi sarcoma 
Oesophageal candidiasis  (or candidiasis of trachea, bronchi or lungs) 
Central nervous system toxoplasmosis (after one month of life) 
HIV encephalopathy 
Cytomegalovirus (CMV) infection; retinitis or CMV infection affecting another organ, with onset at age over one 
month        
Extrapulmonary cryptococcosis (including meningitis) 
Disseminated endemic mycosis (extrapulmonary histoplasmosis, coccidiomycosis) 
Chronic cryptosporidiosis  
Chronic isosporiasis 
Disseminated non-tuberculous mycobacterial infection  
Cerebral or B-cell non-Hodgkin lymphoma 
Progressive multifocal leukoencephalopathy  
Symptomatic HIV-associated nephropathy or HIV-associated cardiomyopathy 
 
1 All clinical events or conditions referred to are described in section below 
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Presumptive and definitive criteria for recognizing HIV/AIDS-related clinical events in 
infants and children with established HIV infection  
Clinical event Clinical diagnosis Definitive diagnosis  
Clinical Stage 1   
Asymptomatic No HIV related symptoms reported and no clinical 
signs on examination. 
Not applicable. 
 
Persistent  generalized 
lymphadenopathy  
Persistent swollen or enlarged lymph nodes >1 cm at 
two or more non-contiguous sites (excluding inguinal) 
without known cause. 
Clinical diagnosis 
Clinical Stage 2   
Unexplained persistent 
hepatosplenomegaly  
Enlarged liver and spleen without obvious cause. Clinical diagnosis 
 
Papular pruritic eruptions Papular pruritic vesicular lesions. Also common in 
uninfected children: scabies and insect bites should 
be excluded.   
Clinical diagnosis 
Extensive wart virus 
infection 
Characteristic warty skin lesions; small fleshy grainy 
bumps, often rough, flat on sole of feet (plantar 






Characteristic skin lesions: small flesh-coloured, 
pearly or pink, dome-shaped or umbilicated growths, 
may be inflamed or red; facial, more than 5% of body 
area or disfiguring. Giant molloscum may indicate 
more advanced immunodeficiency 
Clinical diagnosis 
Fungal nail infections Fungal paronychia (painful, red and swollen nail bed) 
or onycholysis (painless separation of the nail from 
the nail bed.)  Proximal white subungual 
onchomycosis is uncommon without 
immunodeficiency 
Clinical diagnosis 
Recurrent oral ulcerations  
 
Current event plus at least one previous episode in 
past six months.  Aphthous ulceration, typically with a 
halo of inflammation & yellow-grey pseudomembrane. 
Clinical diagnosis 
Unexplained persistent 
parotid enlargement  
 
Asymptomatic bilateral swelling that may 
spontaneously resolve and recur, in absence of other 
known cause, usually painless 
Clinical diagnosis 
Lineal gingival erythema  Erythematous band that follows the contour of the 
free gingival line; may be associated with 
spontaneous bleeding 
Clinical diagnosis 
Herpes zoster  
 
Painful rash with fluid-filled blisters, dermatomal 
distribution, can be haemorrhagic on erythematous 
background, and can become large and confluent. 
Does not cross the midline 
Clinical diagnosis 
Recurrent upper 
respiratory tract infection  
 
Current event with at least one episode in past 6 
months. Symptom complex; fever with unilateral face 
pain and nasal discharge (sinusitis) or painful swollen 
eardrum (otitis media), sore throat with productive 
cough (bronchitis), sore throat (pharyngitis) and 
barking croup-like cough (LTB). Persistent or 
recurrent ear discharge.   
Clinical diagnosis 
Clinical Stage 3   
Unexplained moderate 
malnutrition  
Weight loss: low weight-for-age, up to −2 standard 
deviations from the mean, not explained by poor or 
inadequate feeding and or other infections, and not 
Confirmed by documented loss of body 
weight of –2 standard deviations from the 
mean, failure to gain weight on standard 
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Clinical event Clinical diagnosis Definitive diagnosis  





Unexplained persistent (14 days or more) diarrhoea 
(loose or watery stool, three or more times daily), not 
responding to standard treatment.  
Confirmed by stools observed and 
documented as unformed. Culture and 
microscopy reveal no pathogens. 
Unexplained persistent 
fever (>37.5oC intermittent 
or constant for longer than 
one month) 
Reports of fever or night sweats for longer than one 
month, either intermittent or constant, with reported 
lack of response to antibiotics or antimalarial agents. 
No other obvious foci of disease reported or found on 
examination. Malaria must be excluded in malarious 
areas. 
Confirmed by documented fever of >37.50C 
with negative blood culture, negative malaria 
slide and normal or unchanged chest X-ray, 
and no other obvious foci of disease.  
Oral candidiasis 
(after first 6-8 weeks of 
life) 
Persistent or recurring creamy white to yellow soft 
small plaques which can be scraped off 
(pseudomembranous), or red patches on tongue, 
palate or lining of mouth, usually painful or tender 
(erythematous form).  
Confirmed by microscopy or culture.  
Oral hairy leukoplakia Fine small linear patches on lateral borders of tongue, 
generally bilaterally, which do not scrape off.  
 
Clinical diagnosis 
Lymph node tuberculosis Non acute, painless "cold" enlargement of peripheral 
lymph nodes, localized to one region. May have 
draining sinuses. Response to standard anti- 
tuberculosis treatment in one month. 
Confirmed by histology or fine needle 
aspirate for Ziehl-Nielsen stain or culture.  
Pulmonary tuberculosis 
  
Nonspecific symptoms, e.g. chronic cough, fever, 
night sweats, anorexia and weight loss. In the older 
child also productive cough and haemoptysis. History 
of contact with adults with smear-positive pulmonary 
tuberculosis. No response to standard broad-spectrum 
antibiotic treatment. 
Confirmed by one or more sputum positive 
smear for acid-fast bacilli and/or radiographic 
abnormalities consistent with active 
tuberculosis and/or culture-positive for 
Mycobacterium.  
Severe recurrent bacterial 
pneumonia  
Cough with fast breathing, chest indrawing, nasal 
flaring, wheezing, and grunting.  Crackles or 
consolidation on auscultation. Responds to course of 
antibiotics.  Current episode plus one or more in 
previous 6 months. 
Confirmed by isolation of bacteria from 
appropriate clinical specimens (induced 
sputum, BAL, lung aspirate).  
Acute necrotizing ulcerative 
gingivitis or stomatitis, or 
acute necrotizing ulcerative 
periodontitis  
Severe pain, ulcerated gingival papillae, loosening of 
teeth, spontaneous bleeding, bad odour, and rapid 




No presumptive clinical diagnosis. Diagnosed by chest X-ray: bilateral 
reticulonodular interstitial pulmonary 
infiltrates present for more than two months 
with no response to antibiotic treatment and 
no other pathogen found. Oxygen saturation 
persistently <90%. May present with cor 
pulmonale and may increased exercise-
induced fatigue. Characteristic histology. 
Chronic HIV-associated 
lung disease (including 
bronchiectasis) 
History of cough productive of copious amounts of 
purulent sputum (bronchiectasis only), with or 
without clubbing, halitosis, and crepitations and/or 
wheezes on auscultation 
Confirmed by chest X-ray: may show 
honeycomb appearance (small cysts) and/or 
persistent areas of opacification and/or 
widespread lung destruction, with fibrosis 
and loss of volume.  
Unexplained anaemia 
(<8g/dl), or neutropaenia 
(<0.5 x 109 per litre) 
and/or chronic 
No presumptive clinical diagnosis. Diagnosed on laboratory testing, not 
explained by other non-HIV conditions, not 
responding to standard therapy with 
haematinics, antimalarial agents or 
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Clinical event Clinical diagnosis Definitive diagnosis  
thrombocytopaenia  (<50 x 
109 per litre)  
anthelmintic agents as outlined in WHO 
Integrated Management of Childhood Illness 
(IMCI) guidelines.  
Clinical Stage 4   
Unexplained severe 
wasting, stunting or severe 
malnutrition not adequately 
responding to standard 
therapy  
 
Persistent weight loss not explained by poor or 
inadequate feeding, other infections and not 
adequately responding in two weeks to standard 
therapy. Characterized by: 
visible severe wasting of muscles, with or without 
oedema of both feet, and/or weight-for-height of –3 
standard deviations from the mean, as defined by 
WHO ICMI guidelines.    
Confirmed by documented weight loss of 
moer than -3 standard deviations from the 
mean with or without oedema  
  
Pneumocystis pneumonia  Dry cough, progressive difficulty in breathing, 
cyanosis, tachypnoea and fever; chest indrawing or 
stridor. (Severe or very severe pneumonia as in WHO 
IMCI guidelines). Usually rapid onset especially in 
infants under six months of age. Response to high-
dose co-trimoxazole with or without prednisolone.  
Chest X-ray shows typical bilateral perihilar diffuse 
infiltrates 
Confirmed by: cytology or 
immunofluorescent microscopy of induced 
sputum or BAL or histology of lung tissue.  
 
Recurrent severe bacterial 
infection, e.g. empyema, 
pyomyositis, bone or joint 
infection or meningitis but 
excluding pneumonia 
Fever accompanied by specific symptoms or signs 
that localize infection. Responds to antibiotics. 
Current episode plus one or more in previous 6 
months 
Confirmed by culture of appropriate clinical 
specimen.   
Chronic herpes simplex 
infection; (orolabial or 
cutaneous of more than 
one month's duration or 
visceral at any site)  
 
Severe and progressive painful orolabial, genital, or 
anorectal lesions caused by HSV infection present for 
more than one month.  
 
Confirmed by culture and/or histology 
Oesophageal candidiasis 
(or candidiasis of trachea, 
bronchi or lungs). 
Difficulty in swallowing or pain on swallowing (food 
and fluids).  In young children, suspect particularly if 
oral Candida observed and food refusal occurs and/or 
difficulties or crying when feeding.  
Confirmed by macroscopic appearance at 
endoscopy, microscopy of specimen from 
tissue or macroscopic appearance at 




Systemic illness usually with prolonged fever, night 
sweats, and weight loss. Clinical features of organs 
involved, e.g. sterile pyuria, pericarditis, ascites, 
pleural effusion, meningitis, arthritis or orchiti, 
pericardial or abdominal  
Confirmed by positive microscopy showing 
acid-fast bacilli or culture of Mycobacterium 
TB from blood or other relevant specimen 
except sputum or BAL. Biopsy and histology.  
Kaposi sarcoma  
 
 
Typical appearance in skin or oropharynx of 
persistent, initially flat, patches with a pink or blood-
bruise colour, skin lesions that usually develop into 
nodules.  
Not required but may be confirmed by: 
- typical red-purple lesions seen on 
bronchoscopy or endoscopy;  
- dense masses in lymph nodes, viscera or 
lungs by palpation or radiology;  and 
- histology. 
CMV retinitis or CMV 
infection affecting another 
organ, with onset at age 
over 1 month. 
 
 
Retinitis only.  
CMV retinitis may be diagnosed by experienced 
clinicians: typical eye lesions on serial fundoscopic 
examination; discrete patches of retinal whitening 
with distinct borders, spreading centrifugally, often 
following blood vessels, associated with retinal 
vasculitis, haemorrhage and necrosis.  
Definitive diagnosis required for other sites. 
Histology. Cerebrospinal fluid polymerase 
chain reaction  
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Clinical event Clinical diagnosis Definitive diagnosis  
CNS toxoplasmosis with 
onset at age over 1 month. 
 
Fever, headache, focal neurological signs, 
convulsions. Usually responds within 10 days to 
specific therapy.  
 
Not required but confirmed by computed 
tomography (CT) scan (or other 
neuroimaging) showing single or multiple 






Meningitis: usually subacute, fever with increasing 
severe headache, meningism, confusion and 
behavioural changes that respond to cryptococcal 
therapy. 
Confirmed by CSF microscopy (India ink or 
Gram stain), serum or CSF CRAG test or 
culture. 
HIV encephalopathy  At least one of the following, progressing over at least 
two months in the absence of another illness:  
- failure to attain, or loss of, developmental 
milestones, loss of intellectual ability;  
OR 
- progressive impaired brain growth demonstrated by 
stagnation of head circumference;  
OR 
- acquired symmetric motor deficit accompanied by 
two or more of the following: paresis, pathological 
reflexes, ataxia, gait disturbances.  
Confirmed by neuroimaging (brain CT scan 
or MRI) demonstrating atrophy and basal 





penicilliosis)   
 
 
No presumptive clinical diagnosis. Diagnosed by: 
Histology: usually granuloma formation.  
Isolation: antigen detection from affected 
tissue; culture or microscopy from clinical 
specimen or blood culture. 
Disseminated 
mycobacteriosis,  
other than TB  
No presumptive clinical diagnosis. Nonspecific clinical symptoms including 
progressive weight loss, fever, anaemia, 
night sweats, fatigue or diarrhoea; plus 
culture of atypical mycobacterial species from 
stool, blood, body fluid or other body tissue, 
excluding lung. 
Chronic cryptosporidiosis  
 
No presumptive clinical diagnosis. Confirmed by cysts identified on modified 
Ziehl-Nielsen microscopic examination of 
unformed stool 
Chronic Isospora  No presumptive clinical diagnosis. Confirmed in children with chronic diarrhoea 
by microscopic examination.  
 
Cerebral or B-cell non-
Hodgkin lymphoma 
No presumptive clinical diagnosis. 
 
Diagnosed by CNS neuroimaging: at least 
one lesion with mass effect on brain scan; 
histology of relevant specimen  
Progressive multi focal 
leukoencephalopathy  
No presumptive clinical diagnosis. Diagnosed by progressive nervous system 
disorder (cognitive dysfunction, gait or 
speech disorder, visual loss, limb weakness 
and cranial nerve palsies) together with 
hypodense white matter lesions on 
neuroimaging or positive polyomavirus Jacob 
Creutzfeldt PCR on cerebrospinal fluid 
Symptomatic HIV-
associated nephropathy 
No presumptive clinical diagnosis. Renal biopsy 
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Clinical event Clinical diagnosis Definitive diagnosis  
Symptomatic HIV-
associated cardiomyopathy 
No presumptive clinical diagnosis. Cardiomegaly and evidence of poor left 
ventricular function confirmed by 
echocardiography 
 
PRESUMPTIVE DIAGNOSIS OF SEVERE HIV DISEASE IN INFANTS 
Taken from: WHO case definitions of HIV for surveillance and revised clinical staging and immunological 
classification of HIV-related disease in adults and children. 2007 
 
The presumptive diagnosis is designed for use where access to confirmatory diagnostic 
testing for HIV infection using virological or P24 Antigen for infants and children less than 18 
months is not readily available. It is not recommended for use by clinical care providers who 
are not trained on ART, accredited or certified and experienced in HIV care, and must be 
accompanied by immediate efforts to confirm the HIV diagnosis with the best nationally or 
locally available test.  
 
Clinical criteria for presumptive diagnosis of severe HIV disease among infants and children aged 
under 18 months in situations where virological testing is not available 
 
A presumptive diagnosis of severe HIV disease should be made if: 
• the infant is confirmed as HIV antibody-positive; 
and 
• diagnosis of any AIDS-indicator condition(s)a can be made; 
or 




Other factors that support the diagnosis of severe HIV disease in an HIV-seropositive infant 
include: 
• recent HIV-related maternal death or advanced HIV disease in the mother; 
• CD4 <20%.c 
Confirmation of the diagnosis of HIV infection should be sought as soon as possible. 
 
 
a AIDS indicator conditions include some but not all HIV clinical stage 4 conditions seen in 
children such as Pneumocystis pneumonia, 
oesophageal candidiasis, cryptococcal meningitis, cerebral toxoplasmosis, unexplained 
wasting or malnutrition. 
b Defined in accordance with WHO Integrated Management of Childhood Illness guidelines: 
• Oral thrush: Creamy white soft small plaques on red or normally coloured mucosa which 
can often be scraped off (pseudomembranous), 
or red patches on tongue, palate or lining of mouth, usually painful or tender. 
• Severe pneumonia: Cough or difficult breathing in a child with chest indrawing, stridor or 
any of the general danger signs 
outlined in the WHO Integrated Management of Childhood Illness guidelines: that is 
lethargic or unconscious, not able to 
drink or breastfeed, vomiting and presence or history of convulsions during current illness,. 
• Severe sepsis: Fever or low body temperature in a young infant with any severe sign, such 
as rapid breathing, chest indrawing, 
bulging fontanelle, lethargy, reduced movement, not feeding or sucking breast-milk, 
convulsions, stiff neck. 
c It is unclear how often the CD4 count is lowered in these conditions in HIV-uninfected 
children. 
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Pregnancy and birth 
 
Logistics and linking with Obstetric Services 
Women may come from different geographical locations and therefore referral to and liaison 
with a single maternity facility may not be possible. However, it would be very useful to 
have a key midwife and/or obstetrician involved in DART and to liaise with the DART team. 
It is expected that women will return to the DART clinics around 2 weeks after birth, the 
Outcome of Pregnancy form should be completed at this time. 
 
Advice to women in DART 
Pregnancy is an exclusion criteria for enrolment into DART, also women are advised not to 
become pregnant during the trial because of unknown long-term effects of ART on infant 
outcome. However, we must accept that pregnancies will occur and women must be 
reassured that if they should become pregnant they will continue to receive the medication 
and clinical support provided by DART. They should feel comfortable to inform clinic staff 
should they think they may be pregnant and should feel under no pressure to hide or 
terminate the pregnancy as a consequence of being in DART. If a woman does become 
pregnant in DART, she then requires advice and counselling about: 
1) Continuation of pregnancy 
2) Risk of mother-to-child transmission of HIV infection while in DART 
3) Management of STI during pregnancy and breastfeeding, if she is randomised to STI  
4) ART regimens during pregnancy 
5) Blood tests during pregnancy 
6) Management during delivery 
7) Breastfeeding 
8) Follow-up of her baby 
 
Information for the Woman 
The pregnant woman should be given written information about the risks and benefits of 
pregnancy continuation. This should be accompanied by counselling and oral information. 
Sites will develop and share patient information sheets based on the outlines below. 
 
Most women will have conceived while on ART. They should be counselled about the risk of 
mother-to-child transmission (which will be low [<2%] if they are well and adherent to 
medications). They should also be told about possible risks of exposure to drugs to the 
baby. Explain that although many women in the west have had babies while taking ART with 
no problems, we do not know a lot about the effect of drugs on babies, especially in the 
long term. The information sheet should also contain written information about any 
proposed changes to ART regimens in pregnancy including management of STI, proposed 
follow-up and management during pregnancy and at delivery, management and any 
changes to her of ART regimen as a result of pregnancy, follow-up after delivery (including 
breast-feeding) and follow-up of the baby. 
 
Pregnancy reporting in DART 
Any woman who becomes pregnant in DART should have this reported using an SAE form 
(note that pregnancy is not considered an SAE, just reported on Form 10) with the event 
given as pregnancy (code 60.01) and indicated as type: pregnancy. At the end of pregnancy 
(whether live birth, still birth or abortion) a “resolution” SAE form does not need to be 
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completed. Instead, at the end of a pregnancy (whatever the outcome), an Outcome of 
Pregnancy form (Form 29) should be completed. 
 
It may be that some abortions/deliveries count as SAEs for the mother according to the 
criteria in section 8.8.4.  In such cases an additional (initial) SAE form should be completed 
at the time for the adverse event that is serious (rather than the pregnancy itself), with 
further follow-up or resolution forms as appropriate. 
 
Outcome of Pregnancy form (form 29) 
The Outcome of Pregnancy form asks some questions about storage of specimens from the 
baby. We do not require specific samples to be taken from babies but would like to know if 
samples have been stored as part of clinical care. Similarly HIV-testing of babies is neither 
provided nor requested by DART but if testing has been carried out and the mother is willing 
to share the result we would like to know the result. 
 
Time in labour should be recorded as the approximate number of hours from the onset of 
labour to delivery. 
 
Antiretroviral drugs in pregnancy 
If the woman decides to continue with the pregnancy, her ART medication should be 
reviewed as follows: 
 
First-line regimens: 
ZDV+3TC+NVP There is a lot of experience with these drugs in pregnancy, no 
need to change from this regimen. 
ZDV+3TC+ABC There is limited experience of Abacavir in pregnancy, as it has 
generally been used in women with limited other options. There 
are no clear data to support a change from ABC if the mother is 
well established on the regimen and has had no side effects. GSK 
feel unable to recommend use of ABC in pregnancy due to lack of 
data. In individual cases ABC could be swapped to NVP if a 
clinician had particular concerns. Note: ABC is being continued in 
quite a number of pregnancies reported to the UK register.  
ZDV+3TC+TDF There is limited experience of TDF in pregnancy. In Europe, it is 
mainly used only in women with limited other options. There have 
been some concerns raised from animal experiments about bone 
effects. No specific human foetal effects have been reported so 
far. There are no infant PK data. Women could be given the 
option to substitute NVP for TDF. TDF is generally being continued 
in pregnancies reported to the UK register.  
D4T If a woman is taking d4T (i.e. ZDV was replaced for toxicity), 
consideration could be given to replacing this again with ZDV, 
mainly because the latter has proven efficacy for prevention of 
MTCT. However, the risk of anaemia and risk of bleeding 
associated with the proposed place of birth must also be taken 
into account before this decision is made. Thus this decision 





ddI+d4T is contraindicated in pregnancy because of the risk of lactic 
acidosis and should be appropriately replaced by another NRTI 
combination (the easiest is likely to switch back to ZDV from d4T) 
ddI OK if not with D4T 
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EFV should be switched to NVP (in fact there is an argument for using 
NVP instead of EFV if there is a risk of pregnancy).  
KAL is being used in Europe but there is less experience than with 
some other PIs. 
 
Women should be encouraged to adhere well to their ART regimen and to continue to take 
all their medication, and not to miss any doses.  
 
Pregnancy and DART randomisations 
CMO/LCM 
Whether the woman is in the CMO or LCM arm, pregnancy would normally be a clinical 
indication to undertake a full blood count and haemoglobin as per normal ANC practice. If a 
woman is receiving NVP a clinician may consider requesting LFTs for a woman in the CMO 
arm.  
 
In addition, routine tests such as VDRL, STD screening, urine testing etc. should be 
preformed according to local antenatal practice. Tetanus toxoid and iron/folate should also 
be administered as per national ANC guidelines. These tests will normally be provided by the 
woman’s ANC clinic rather than the DART clinic. 
 
For women in LCM, it should be noted that CD4 counts fall during pregnancy because of 




Pregnancy and breastfeeding are exclusion criteria for the STI randomisation. 
 
As shown on the flow sheets a pregnancy test should be carried out for all women before 
the start of any STI. If the result is positive they should not commence the scheduled STI. 
 
Should a woman be found to be pregnant during an STI this will normally be during the first 
trimester. Such women should be told that they should go back onto ART and take it 
continuously during pregnancy and breast-feeding. Restart of ART may be delayed until 
after the first trimester, if the woman is well. STIs should only be recommenced after 
breast-feeding has ceased. 
 
Ante-natal care (ANC)/ management in pregnancy 
Ante-natal care and infant feeding counselling should be provided as per national guidelines 
(reference documents from respective ministries of health).  
 
PMTCT information will need to be modified in view of the ongoing ART to the mother and 
the ART drugs (dosages and duration) we intend to use in the newborn infant.  
 
Women will normally be referred to an antenatal clinic. However, it may be useful, if there 
are reasonable numbers of pregnant women, for them to be reviewed in the DART clinic 
with a midwife or obstetrician and receive ANC in DART. The DART clinic should ensure that 
the woman informs their antenatal clinic that they are enrolled in DART. Sites may chose to 
provide a referral letter for the woman to give to their ANC clinic giving some details of 
DART including the ART regimen. There should also be details of how the clinic can contact 
the DART team for further information. Sites may choose to develop links with ANC clinics to 
facilitate patient management and exchange of information. 
 
The frequency of ANC visits will depend on the stage of the pregnancy and should follow 
local practice. DART visits should continue as per normal during pregnancy, and follow-up 
nurse and doctor forms should be completed in the normal way. 
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Malaria in pregnancy 
Malaria infection in pregnancy poses a substantial risk to the mother, the foetus and the 
newborn infant. Pregnant women are less capable of coping with and clearing malaria 
infections. In areas of low transmission of P. falciparum, where levels of acquired immunity 
are low, women are susceptible to attacks of severe malaria, which may result in stillbirths 
or spontaneous abortions, or the death of the mother. In areas of high P. falciparum 
transmission, levels of acquired immunity tend to be high and women may have 
asymptomatic infections, which may result in maternal anaemia and placental parasitaemia. 
Both of these conditions can lead to low birth weight, an important contributor to neonatal 
mortality. 
 
Sites in Uganda (where malaria is endemic) and in Zimbabwe if women are travelling 
outside Harare should consider implementing intermittent treatment with 3-dose treatment 
regimens of sulfadoxine-pyrimethamine: once in the second and twice in the third trimester 
to prevent malaria in pregnancy. In HIV-positive women, the 3-dose treatment is 
significantly more efficacious than the 2-dose regimen. Such prophylaxis may be provided by 
the antenatal clinics. 
 
Management of HIV infection during pregnancy 
The normal DART guidelines with respect to clinical and/or CD4 should be followed for 
switching ART. However, as noted above, CD4 counts normally fall during pregnancy, 
so this should be borne in mind when considering switching for immunological failure in LCM 
patients. Note also that early side-effects of a new ART regimen may be less tolerable in 
pregnancy. 
 
Management at Delivery 
IT IS VERY IMPORTANT that the pregnant woman and DART team link up with an 
appropriate (recommended) delivery institution, so that: 
1) Midwives/doctor etc are aware that the mother is on ART and the need to 
continue with it during the peri-partum and the post-partum period. 
2) Delivery is actively managed, with avoidance of PROM and foetal scalp 
electrodes, but with treatment of infections, etc. 
3) Midwife or a doctor who supervises the delivery need to be informed about the 
mother’s ART and the infant ART prophylaxis  
4) Infant prophylaxis be given at the appropriate time 
5) DART team (2 members identified to care for pregnant women (most likely a 
nurse and a doctor)) to be the key liaison personnel with the place/institution 
where the mother delivers, to ensure that pregnancy and outcome data are 
retrieved from the maternity notes as appropriate, blood specimens from the 
mother and infant are taken and stored if agreed, and to ensure that the mother 
and infant are given the correct designated ART 
 
It is anticipated that women should attend the DART clinic 10 days to 2 weeks after giving 
birth. The outcome of pregnancy form should be completed at this time. 
 
Postpartum 
The mother should be followed-up and treated according to the DART protocol and MOP. 
Family planning and counselling services should be offered to all women in the postpartum 
period as per national guidelines. 
 
Currently infants cannot be followed up under the DART protocol, however, we plan to 
develop a substudy for follow-up. Infants should be managed (including monitoring for 
toxicity and infection status) according to local guidelines. Mothers should be counselled 
about options for HIV testing of infants. Cotrimoxazole prophylaxis should be started at 4 to 
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6 weeks, regardless of knowledge of HIV status. Although HIV testing of infants cannot be 
carried out as part of DART the optimal way is to do HIV – DNA PCR, or a viral load test. 
Minimum testing would be to perform this in any child for whom one had clinical concerns 
and were considering starting ART before 18 months of age. If available, testing should be 
done at 6 weeks and again around 3 months after stopping breast-feeding, or according to 
WHO/national guidelines. Cotrimoxazole prophylaxis should be continued until after breast-
feeding has stopped and a negative test-result obtained for the baby. 
 
Breast Feeding 
We do not have enough data about breast-feeding while on ART. We hope that breast-milk 
viral load will be suppressed as the mother is on triple ART, so the risk of transmission 
would be small. We hope that the level of ongoing ART exposure to the infant would also be 
small (although this should help prevent transmission during breast-feeding), but this needs 
to be confirmed with PK studies. It would be very useful to monitor VL and drug levels in 
breast-milk. However, this needs to be a separate substudy (part of PK substudy or could be 
part of follow-up of infant protocol) and would need consent, so cannot be implemented at 
present.  
 
As per national guidelines women should be counselled about the possible risks (exposure of 
the infant to drugs and possibly to HIV) and known benefits of breast-feeding. The option of 
rapid weaning to reduce the duration of breast-feeding should be discussed. The 
transmission risks for women on triple-ART may be considerably reduced compared to 
women on no ART.  
 
Antiretroviral therapy during delivery and postnatally 
Mother 
The woman should continue ART throughout delivery as regularly as possible and also in the 
postnatal period. As the woman is on triple therapy, additional NVP or ZDV for prevention of 
MTCT (as per local guidelines) should NOT need to be given to the mother. 
 
Infant 
The most appropriate prophylaxis for the baby born to a mother taking triple ART is not 
completely clear and there are no trials to inform this decision. In Europe and US, babies are 
generally given one or more of the same drugs that the woman is receiving, and in 
particular, receive ART known to reduce MTCT (e.g. NVP if the mother is on NVP or ZDV +/- 
3TC if the mother is on these NRTIs). However, this is in a setting where most women have 
VL carefully monitored and will have VL below the level of detection. In the DART trial the 
main danger for transmission is for women who have detectable virus and are failing their 
regimen.  
 
Therefore there is an argument that prophylaxis for babies is best undertaken with a 
different drug to those the woman is receiving. For women on first-line TDF+CBV, NVP 
should be given to THE INFANT ONLY WITHIN 4 HOURS OF BIRTH, as it will not 
have been given to the mother. Babies could also receive ZDV+/-3TC for 1 week as well 
as this single dose of NVP, starting within 4 hours of birth. However, giving all 3 may be 
difficult as liquid formulations have to be obtained. NVP could be given as part of a national 
program. 
 
For mothers taking NVP+ZDV+3TC, NVP post-exposure prophylaxis should be given for the 
baby starting at 48 hours. ZDV+/- 3TC could be added for 1 week, if this is feasible and 
available, as there are few other alternative regimens.  
 
Sites may deviate from this policy if individual circumstances indicate an alternative, but 
should inform the MRC CTU of their intentions. 
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Patient information sheets 
Here are some ideas, please annotate / change to more appropriate language etc. 
 
Pregnancy in the DART trial 
 
As a woman in the DART trial you will have been advised against pregnancy because of the 
slight possibility that your anti-HIV drugs might harm your baby. However, for most of these 
drugs there is no clear evidence that they may cause any problems. If you are taking a drug 
that is known to have a risk your doctor will change that to another anti-HIV drug. If you 
have become pregnant you will continue to receive anti-HIV drugs within the DART trial as 
well as continued clinical care and support. 
 
What is the risk of my baby being infected with the HIV? 
 
If a mother is not receiving any treatment and she breastfeeds her baby then there is 
at least a one in three chance the baby will be infected with HIV. The risk to the baby can 
be higher if the mother is sick with a high level of virus in the blood. 
 
If a mother is receiving anti-HIV treatment, as you are in the DART trial, and not 
missing any doses, then there is likely to be a very low risk of the baby being infected with 
HIV (only around one in one hundred in women who do not breast-feed, and may also be as 
low in women who continue on treatment whilst they breast feed, but we do not know for 
sure yet). 
 
Will taking anti-HIV treatment in pregnancy cause any harm to my baby? 
 
Until now there have been no reported increases in any kind of birth abnormalities in babies 
born to women taking ART in pregnancy. However this is still something that is being closely 
looked at. We know that some of the drugs may cause problems to babies if the mother is 
taking them during pregnancy and your doctor will discuss changing your drugs if you are 
taking one of these medicines: 
 
Some drugs have been used a lot in pregnant women and we think they are probably safe, 
although the long-term effects are not yet known.  
 
Combivir+Nevirapine: Many women have become pregnant around the world whilst 
taking this combination: Most have remained very well, but some 
women and babies do get anaemic with ZDV.  
 
Combivir+Abacavir: There is less experience of abacavir use in pregnancy, so far no 
specific problems have been reported. Your doctor may 
recommend switching from ABC to NVP. 
 
Combivir+Tenofovir: There is less experience of TDF in pregnancy. So far no specific 
problems have been reported in babies. Concern that TDF could 
affect the baby’s bones has been expressed because it has been 
seen in some baby animals whose mothers received TDF. 
 
Other drugs: 
Efavirenz: This is known to cause abnormalities of the brain in animals, 
although not reported in humans. If you are taking this drug, your 
doctor will want to change it as soon as possible.  
 
Stavudine + These should not be given together to pregnant women as it may 
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didanosine:  make them sick, especially late in pregnancy. Your doctor will 
probably change one of these drugs if you are taking them. 
 
Kaletra: If you are taking Kaletra your doctor will recommend that you 
continue to take it throughout pregnancy.  
 
 
Long-term follow-up of babies born in DART 
As there may be rare effects of the treatment that we do not yet know about, you may be 
asked to join a long-term study so that we can follow up your child and make sure that they 
remain well over the next few years. 
 
What do I do about my ART when it comes to the delivery of the baby? 
 
Its very important to continue to take your medicines throughout pregnancy and not miss 
any of your doses, this is the best way to keep you well and to have the smallest risk of HIV 
passing to your baby. This is especially important around the time of delivery as this is when 
there is the highest risk of the virus passing to the baby. Always keep your medicines with 
you and don’t stop taking them at any time. Continue to take them at the regular time 
during labour, and after the baby is born. This is when they are most needed to protect the 
baby from the virus. 
 
Will my baby need to take any medicines? 
 
Your doctor may recommend the anti-HIV drugs for your baby shortly after birth. This may 
include NVP being given to your baby (but not to you) as part of the national program. Your 
doctor will tell you what your baby will need to take and when.  
 
You should also be offered cotrimoxazole for your baby from 4 to 6 weeks after birth. If 
your baby should become HIV infected despite the low risk, this drug would help protect 
your baby from other infections which are common in babies with HIV infection.  
 
 
Is it safe for my baby if I continue on my ART whilst I breast feed? 
 
It is likely that the risk of HIV infection passing to your baby whilst you breast-feed whilst 
taking ART will be very small. However, we do not know this for sure as studies to look at 
this more closely are only currently underway. We may ask to collect samples of breast-milk 
to check for levels of the anti-HIV medicines in breast-milk, as very little is known about 
this. 
 
You will receive advice from doctors and nurses about HIV transmission and breastfeeding. 
If you breastfeed, you will be given advise about when to stop and about mixed feeding. 
[sites to add/modify as appropriate] 
 
Much more information about the safety of breast-feeding on ART will come out over the 
next few years, ask your nurse / doctor for an update. 
 
How do I find out whether or not my baby is infected with HIV? 
 
[sites to add/modify as appropriate] 
 
Can my baby receive treatment if he/she is infected? 
 
[sites to add/modify as appropriate] 
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Other questions 
You may have other questions about being pregnant on ART? Please don’t hesitate to ask 
your nurse / doctor who may be able to answer them. They may also be able to put you in 
touch with another woman who has been pregnant / had a baby on ART so you can talk 
about the experience with her.  
 
 
